 
I8F-MC-GPGA(f) Clinical Pharmacology Protocol 
 
 A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, 
Tolerability,  Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in 
Patients with Type 2 Diabetes  Mellitus  
 
[STUDY_ID_REMOVED]  
 
Approval Date: 06- Feb-2017 
 
 
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 1
LY3298176Protocol I8F-MC-GPGA
A Single -and Multiple -Ascending Dose Study in Healthy  
Subjects to Investigate the Safety , Tolerability , 
Pharmacokinetics, and Pharmacody namics of LY3298176 
andMultiple Dose sinPatients with Ty pe 2 Diabetes 
Mellitus
Confidential Information
The information contained in this protocol is confidential and is intended f or the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
LY3298176 , unless such persons are bound by a confide ntiality agreement with Eli Lilly 
and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company request s consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY3298176
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly: 
17February 2016
Amendm ent (a) Electronical ly Signed and Approved by Lilly :  17 April 2016
Amendm ent (b) Electronically Signed and Approved by Lilly : 23 April 2016
Amendm ent (c ) Electronically Signed and Approved by Lilly :  03 June 2016
Amendm ent (d) Electronically Signed and Approved by Lilly: 26 July 2016
Amendm ent (e) Electro nically Signed and Approved by Lilly: 03 September 2016
Amendm ent (f) Electronically Signed and Approved by Lilly
on approval date provided below.
Approval Date: 06-Feb-2017 GMT
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 2
LY3298176Table of Contents
A Single -and Multiple -Ascending Dose Study  in Healthy  
Subjects to Investigate the Safety ,Tolerability , 
Pharmacokinetics, and Pharmacody namics of LY3298176 
and Multiple Doses in Patients with Ty pe 2 Diabetes Mellitus
Section Page
Protocol  I8F-MC-GPGA A Single -and Mul tiple-Ascending Dose Study  in 
Healthy Subjects to Invest igate the Safet y, Tolerabili ty, 
Pharmacokinet ics, and Pharmacodynamics of LY3298176 and 
Multiple Doses in Pat ients with Type 2 Di abetes Mellitus ................................................... 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 8
2. Sched ule of Act ivities....................................................................................................... 11
3. Introduction ...................................................................................................................... 17
3.1. Study  Rati onale ............................................................................................................ 17
3.2. Background .................................................................................................................. 17
3.3. Benefit/Risk Assessment .............................................................................................. 19
4. Object ives and Endpo ints.................................................................................................. 20
5. Study  Design ..................................................................................................................... 21
5.1. Overall Design ............................................................................................................. 21
5.1.1. Single-Ascending Dose Study  in Healt hy Subjects (Part A) .................................. 23
5.1.2. Multiple-Ascending Dose Study  in Healt hy Subjects (Part B) .............................. 24
5.1.3. Multiple-Dose Evaluat ion in Patients with Type 2 Diabetes 
Mellitus (Part C) .................................................................................................. 24
5.2. Number of Participants .................................................................................................24
5.3. End of Study  Definit ion............................................................................................... 24
5.4. Scientific Rationale for Study  Design ........................................................................... 25
5.5. Justification for Dose ................................................................................................... 25
6. Study  Popul ation............................................................................................................... 28
6.1. Inclusio n Cri teria.......................................................................................................... 28
6.1.1. All Study  Parti cipants .......................................................................................... 28
6.1.2. Patients wi th T2DM (Part C only) ........................................................................ 29
6.2. Exclusio n Cri teria........................................................................................................ 29
6.2.1. All Study  Parti cipants .......................................................................................... 29
6.2.2. Patients wi th T2DM (Part C only) ........................................................................ 31
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 32
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 3
LY32981766.3.1. Meals and Dietary  Restri ctions............................................................................. 32
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 32
6.3.3. Activity................................................................................................................ 32
6.4. Screen Failures ............................................................................................................. 32
7. Treat ment .......................................................................................................................... 33
7.1. Treatment Administered ............................................................................................... 33
7.1.1. Packaging and Labeling ....................................................................................... 33
7.2. Method of Treatment Assignment ................................................................................ 34
7.2.1. Selection and Timing o f Doses ............................................................................. 34
7.3. Blinding ....................................................................................................................... 34
7.4. Dose Modi fication........................................................................................................ 35
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 35
7.6. Treatment Compliance .................................................................................................35
7.6.1. Dose Deci sion/Escalat ion..................................................................................... 36
7.7. Concomitant Therapy ................................................................................................... 37
7.8. Treatment after the End of the Study ............................................................................ 37
8. Discontinuati on Cri teria .................................................................................................... 38
8.1. Discontinuati on from Study  Treatm ent......................................................................... 38
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Patients/Subjects .................................38
8.2. Discontinuati on from the Study .................................................................................... 38
8.3. Patients/Subjects Lost to Follow -up.............................................................................. 39
9. Study  Assessments and Procedures ................................................................................... 40
9.1. Efficacy Assessments ................................................................................................... 40
9.2. Adverse Events ............................................................................................................ 40
9.2.1. Serious Adverse Events ........................................................................................ 41
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 42
9.2.2. Com plaint Handling ............................................................................................. 42
9.3. Treatment of Overdose ................................................................................................
.42
9.4. Safety........................................................................................................................... 42
9.4.1. Laboratory  Tests .................................................................................................. 42
9.4.2. Physical Examinat ion........................................................................................... 42
9.4.3. Vital Signs ........................................................................................................... 42
9.4.3.1. Body  Weight .................................................................................................. 43
9.4.4. Electrocardiograms .............................................................................................. 43
9.4.5. Safety Moni toring ................................................................................................ 44
9.4.6. Immunogenicit y Assessments .............................................................................. 45
9.4.7. Hypersensi tivity Reacti ons................................................................................... 45
9.4.7.1. Inject ion-Site Reacti ons.................................................................................. 45
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 4
LY32981769.4.8. Glucose Moni toring ............................................................................................. 45
9.4.8.1. Part A ............................................................................................................. 45
9.4.8.2. Parts B and C .................................................................................................. 45
9.4.8.3. Hyperglycemia and Hy poglycemia Reporting ................................................. 46
9.4.9. Nausea and Vomit ing........................................................................................... 47
9.4.10. Elevated Lipase or Amylase ................................................................................. 47
9.5. Pharmacokinet ics......................................................................................................... 47
9.5.1. Bioanalysis ........................................................................................................... 48
9.6. Pharm acodynamics ...................................................................................................... 48
9.6.1. Glucose Sam ples.................................................................................................. 48
9.6.1.1. Oral Glucose Tol erance Test (Parts B and C) .................................................. 48
9.6.1.2. 7-Point Gl ucose Moni toring (Parts B and C) ................................................... 49
9.6.2. Gastri c Em ptying (Parts B and C) ........................................................................ 49
9.6.2.1. Bioanalysis ..................................................................................................... 49
9.6.3. Bone Bio markers ................................................................................................
.49
9.7. Genet ics....................................................................................................................... 49
9.8. Biomarkers ................................................................................................................... 50
9.9. Heal th Economics ........................................................................................................ 50
10. Statistical Considerations and Data Analysis ..................................................................... 51
10.1. Sample Si ze Determinat ion.......................................................................................... 51
10.2. Popul ations for Analyses .............................................................................................. 51
10.2.1. Study  Parti cipant Disposit ion............................................................................... 51
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 51
10.3. Statistical Analyses ...................................................................................................... 51
10.3.1. Safety Analyses .................................................................................................... 51
10.3.1.1. Clinical Evaluation of Safet y.......................................................................... 51
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 52
10.3.2. Pharmacokinet ic Analyses .................................................................................... 52
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 52
10.3.2.2. Pharmacokinet ic Statistical Inference ............................................................. 52
10.3.3. Pharmacodynamic Analyses ................................................................................. 53
10.3.3.1. Pharmacodynamic Parameter Estimation ........................................................ 53
10.3.3.2. Pharmacodynamic Statistical Inference ........................................................... 53
10.3.4. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 54
10.3.5. Evaluat ion of Immunogenicit y............................................................................. 54
10.3.6. Interim Analyses .................................................................................................. 54
11. References ........................................................................................................................ 55
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 5
LY3298176List of Tables
Table Page
Table GPGA.4.1 Object ives and Endpo ints....................................................................... 20
Table GPGA.5.1. Margin of Safet y for Subcutaneous Administration of LY3298176 
Based on Body  Surf ace Area and Predi cted Exposure ............................. 26
Table GPGA.5.2. Updated Margin of Safet y for Subcutaneous Administration of 
LY3298176 Based on Preliminary Human PK Da ta................................ 27
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 6
LY3298176List of Figures
Figure Page
Figure GPGA.5.1. General study  design for Protoco l I8F-MC-GPGA. .................................22
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 7
LY3298176List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 56
Appendix 2. Clinical Laboratory  Tests ........................................................................ 60
Appendix 3. Study  Governance, Regulatory , and Ethi cal Considerati ons.................... 61
Appendix 4. Clinically Sig nificant Adverse Effects .................................................... 64
Appendix 5. Pancreat ic Monitoring ............................................................................ 66
Appendix 6. Blood Sam pling Summary ...................................................................... 69
Appendix 7. Reasonably Ant icipated Seri ous Adverse Events .................................... 72
Appendix 8. Protocol  Amendment I8F -MC-GPGA(f) Summary
A Single -and Mul tiple-Ascending Dose Study  in Healthy Subjects 
to Investigate the Safety , Tol erabili ty, Pharmacokinet ics, and 
Pharmacodynamics o f LY3298176 and Mult iple Doses in Pat ients 
with Type 2 Di abetes Mellitus ................................................................ 73
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 8
LY32981761.Protocol Synopsis
Title of Study:   
A Single -and Multiple -Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, 
Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients with Type 2 Di abetes 
Mellitus
Rationale:
LY3298176 is  glucose -dependent insulinotropic polypeptide (GIP) and glucagon -like peptide -1 (GLP -1) 
receptor coagonist being developed as a weekly  treatment for type 2 diabetes mellitus (T2DM).  This first -in-human 
study of LY3298176, I8F -MC-GPGA (GPGA), will investigate the safety, tolerability, pharmacokinetics (PK), and 
pharmacodynamics (PD) of LY3298176 administered as subcutaneous (SC) injections in healthy subjects and in 
patients with T2DM.
Objectives /Endpoint s:  
Primary Objective Endpoints
To investigate the safety and tolerability following 
single and multiple SC doses of LY3298176 
administered to healthy subjects and patients with 
T2DMAdverse event and safety glucose monitoring.
Secondary Objectives Endpoints
To characterize the PK of LY3298176 following SC 
doses of LY3298176 inhealthy  subjects and patients 
with T2DMBlood samples will be evaluated for LY3298176 
concentration for the assessment of LY3298176 PK 
parameters using a noncompartmental met hod of 
analy sis.
To investigate the PD effects of LY3298176 following 
multiple SC doses of LY3298176 administered to 
healthy  subjectsGlycemic control (including fasting glucose; glucose 
and insulin during an OGTT), gastric emptying using 
acetaminophen, w eight, lipids, adiponectin, blood urea 
nitrogen, and cortisol.
To investigate the PD effects of LY3298176 following 
multiple SC doses of LY3298176 administered to 
patients with T2DMGlycemic control (including fasting glucose; glucose 
insulin during an OGTT , and hemoglobin A1C ), gastric 
empty ing using acetaminophen, weight, lipids, 
adipo nectin, blood urea nitrogen, and cortisol.
Abbreviations:  AUC =area under the concentration versus time curve; ECG =electrocardiogram; OGTT =oral 
glucose tolerance t est; PD =pharmacodynamic; PK =pharmacokinetic; SC =subcutaneous; T2DM =type 2 
diabetes mellitus.
Summary of Study Design:   
Study GPGA is a Phase 1, multiple -site, patient -/subject -and investigator -blind, placebo -controlled, randomized, 
parallel -dose group, single -ascending dose (SAD; Part A) ,and a 4-week multiple -ascending dose (MAD; Part B) 
study in healthy subjects, and a 4 -week multiple -dose evaluation in patients with T2DM (Part C).   Part B will 
evaluate Trulicity ®(dulaglutide) as a positive control for PDof GLP-1 pharmacology.
CCI
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 9
LY3298176Treatment Arms and Duration:   
Part A will consist of up to 6 escalating single -dose levels of LY3298176 or placebo in healthy subjects.  
Approximately 48subjects will be randomized into 6 groups (Cohor ts A through F).
In Part B, approximately 40 healthy subjects in Cohorts A through E will be administered 4 weekly SC doses 
within the dose and exposure range of the SAD (Part A) .
Up to 3 additional cohorts of approximately 8 subjects each may be utilized to explore the full single (Part A) or 
multiple (Part B) dose range planned or to evaluate dose titration regimens in Part B of the study.  The additional 
cohorts will be assigned the next available letter designation. 
Part C of the study will be a 4 -
week multiple -dose evaluation of LY3298176 in approximately 20 patients with 
T2DM.
Number of Patients /Subjects:
Approximately 143healthy  subjects and up to approximately 25 patients with T2DM may be enrolled so that 
approximately 112 healthy  subjects and 20 patients complete the study.
Statistical Analysis:
PK and PD analyses will be conducted on the full analysis set.  Safety analyses will be conducted for all enrolled 
patients/subjects whether or not they completed all protocol requirements.
Sample Size: Approximately 143 healthy  subjects may  be enrolled in Parts A and Part B to achieve the objectives 
of each part of the study.  Approximately 25 T2DM patients may be enrolled in Part C to achieve study objectives.  
The replacement patient/subj ect will be assigned to receive the treatment of the dropout.
For each study part, any dropout may be replaced so that the targeted numbers of patients/subjects for safety review 
and data collection may be achieved.  The replacement patient/subject will be assigned to receive the treatment of 
the dropout.
The sample sizes for each part of the study were chosen to provide adequate placebo control for each dosing 
occasion and are considered sufficient to evaluate the primary objective of this study.
Safety:   All investigational product –and protocol procedure –related adverse events will be listed, and if the 
frequency  of events allows, safety data will be summarized using descriptive methodology.   Safety parameters that 
will be assessed include safety laborato ry parameters, v ital signs, electrocardiogram parameters ,and injection -site 
reactions .
Pharmacokinetics:   PK parameter estimates for LY3298176 will be calculated by standard noncompartmental 
methods of analysis.  The primary parameters for analysis will be maximum drug concentration (C max),area under 
the concentration -time curve (AUC) , and time to Cmax(Tmax) of LY3298176.  Other parameters, such as half -life, 
apparent clearance, and apparent volume of distribution, may be reported.
For single -and multi ple-dose parts of the study, PK dose proportionality will be assessed separately.  
Log-transformed C maxand AUC of LY3298176 will be evaluated using a power model to estimate ratios of 
dose-normalized geometric means and corresponding 90% confidence interv als (CIs ).  The estimated ratio of 
dose-normalized geometric means of PK parameters between the highest and lowest doses will be used to assess 
dose proportionality.
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 10
LY3298176The parameter Tmaxof LY3298176 will be analyzed using a nonparametric method.
For Parts A, B, and C, all PK parameters will be summarized using descriptive statistics.
Pharmacodynamics:   Inferences will be sought regarding the ability of LY3298176 to reduce fasting or dynamic 
glucose together with the effects on insulin.  Such effects will be explored over different doses of LY3298176.
The AUC for glucose and insulin during an oral glucose tolerance test (OGTT) will be calculated using the 
trapezoidal rule.
Gastric emptying of LY3298176 will be evaluated using acetaminophen parameters .  The parameter estimates for 
acetaminophen will be calculated by standard noncompartmental methods of analysis .  The primary parameters for 
analy sis will be the C max, the AUC, and the Tmaxof acetaminophen.  Other parameters, such as half -life, apparent 
clearan ce, and apparent volume of distribution, may be reported.
The PD parameters from each part of the study will be analyzed separately.  PD parameters from placebo -treated 
patients/subjects within each part of the study will be pooled for the final analysis. Absolute values as well as 
change from baseline in each parameter will be analyzed using mixed -effects models to evaluate treatment effects as 
well as treatment comparisons.  The main comparisons will be between each LY3298176 -treated group and placebo 
group.
Baseline-adjusted C maxof acetaminophen (ratio to Day -1 value) will be calculated and log -transformed to compare 
the gastric emptying effect of LY3298176 to that of dulaglutide.  A mixed- model repeated -measure with treatment, 
day, and treatment-by -day interaction as fixed effects, patient/subject as random effect, and baseline (Day -1) as 
covariate will be used to perform the analysis.  Least -squares means as well as 95% CIs will be reported.
The parameter Tmaxof acetaminophen will be analyzed using a nonparametric method .
All PD parameters, including the baseline -corrected parameters, will be summarized and tabulated by treatment 
group and day.  Summary statistics will be provided.
Pharmacokinetics/Pharmacodynamics:   PK/PD modeling may be evaluated to characterize the exposure -response 
relatio nships between LY3298176 concentrations and various PD endpoints, provided data are sufficient.
Immunogenicity:   The frequency of antibody formation to LY3298176 will be determined.  If a neutralization assay 
is performed, the frequency of neutralizing antibodies will be determined.  The relationship between the presence (or 
absence) of antibodies and clinical parameters will be assessed.  Likewise, the relationship between the presence of 
antibodies and the PK pa rameters and PD response to LY3298176 will be assessed.
Interim Analysis:   Access to the data is scheduled to occur after ever y dosing session.  The purpose of these reviews 
is to review the safety data and determine the dose for the next dosing session.  The investigator and the Lilly 
sponsor team will make the determination regarding dose escalation based upon their review of the safety and 
tolerability data.  The investigator will remain blinded ,and the Lilly sponsor team will be unblinded during these 
reviews.
I8F-MC-GPGA (f)Clinical Pharmacology Protocol Page 11
LY32981762.Schedule of A ctivities
I8F-MC-GPGA(f) Clinical Pharmacology Protoco l Page 12
LY3298176Study Schedule Protocol I8F -MC -GPGA, Part A
Procedure Screening a Baseline Treatment a Follow -upb
Days −1 1 2 3 4 5 6 8 15 ± 1 29± 3 43 ± 3 ETc
Study informed consent X
Medical history X
Physical examination X
Height and weight d X X X X X X X
Admit to CRU X
Medical assessment o X Predose X X X X X X X X X X
Discharge from CRU e X
Clinical safety lab f X Predose X X X X X X
Glucose only g(hr) 8 X X X X
Vital signs (BP/PR) h(hr) X Predose, 1, 4, 8, and 12 X X X X X X X X X X
Body temperature (hr) X X Predose , 8
ECGs i(hr) X Predose, 8 X X X X X X X X X X
Administer study drug j X
PK sampling k(hr) Predose, 8 X X X X X X X X X X
Point of care safety 
glucose sampling lX XX X X X
Lipid panel m Predose X
Fasting insulin m Predose X
Pharmacogenomic sample X
Nonpharmacogenetic 
sampling (storage) nPredose X
Immunogenicity X X X X X
AEs/concomitant 
medicationsX X X X X X X X X X X X
Abbreviations :  AE = adverse event; BP = blood pressure; CRU = clinical research unit; ECG =electrocardiogram; ET = early termination; lab=laboratory;
PK= pharmacokinetics; PR = pulse rate .
aScreening shall be completed up to 28 days before study  enrollment .  Clinical tests will be repeated if dosing is>28 days from initial screening.
bFollow-up visit shall be completed after at least 28 days from dose of study drug.
cSubjects who discontinue early will be encouraged to return for a follow -up visit at least 28 days after study drug administration.
dHeight measured at screening only.   Weigh t will be measured in a consistent way always predose.   Scale needs to be calibrated (refer to Section 9.4.3.1 ).
eThe day  of discharge may be changed after review of preliminary safety and/or PK data.  On Day 4, subjects may be discharged after the morning procedures
are completed.  Subjects may be retained in -house longer than Day 4 at the investigator’s discretion.
I8F-MC-GPGA(f) Clinical Pharmacology Protoco l Page 13
LY3298176fClinical safety laboratory measures include chemistry, hematology, and urinalysis panels.  Blood samples will be taken predose on thedosing day.  Subjects
will be required to fast for at least 8 hours before each blood sample is drawn.
gNonfasting g lucose samples will be taken with triplicate ECGs and PK time points on the days that no clinical safety laboratory samples are taken.
hVital measurements whose nominal times are not listed in the schedule should be taken before PK samples scheduled on the same day.  
BP and PR 
measurem ents will be taken after approximately 5 minutes in the supine position.
iA single local safety ECG will be measured at screening, Day 29 ,andDay 43 (follow -up) or ETvisit.  Triplicate ECGs will be obtained at predose (Day  1),
and 8, 24, 48, 72, 96, 120, 168 , and 336 hours post dose at a time matched to predose .  TheDay 1predose ECG swill be taken in triplicates ever y 15 minutes 
for 1 hour to establish a baseline.  ECGs must be recorded before collecting any blood for safety or PK samples and close t o the time of the blood draw.   
Subjects must be supine for approximately 5 to 10 minutes before ECG collection and remain supine but awake during ECG collection.
jStudy drug will be administered after an overnight fast of at least 8 hours .
kPK samples will be obtained predose and 8 and 24hours postdose, and approximately 48, 72, 96, 120, 168, and 336hours postdose and at the follow -up visit s
on Day s29 and 43.
lPoint of care saf ety glucose sampling at pre meal (breakfast, lunch, and dinner) and before bedtime during CRU stay (Days 1 to 3).  Prebreakfast samples only 
will be collected on Days 4, 5,and 6.
mSubjects will be required to fast for at least 8 hours before each blood sample is drawn for lipid panel and fasting insulin .  Lipid pane l includes fasting 
triglycerides, total cholesterol, low -
density  lipoprotein cholesterol, and high -density lipoprotein cholesterol.
nNonpharmacogenetic samples will be collected predose and while fasting for at least 8 hours before each blood sample is drawn.
oAssessment sof injection site reactions will be included in the medical a ssessments , except screening.
I8F-MC-GPGA(f) Clinical Pharmacology Protoco l Page 14
LY3298176Study Schedule Pro tocol I8F -MC -GPGA Parts B and C
Procedure Screen aPrestudy Baseline Treatment a Follow -up
Days Before 
Day −2−2 −1 1 2 3 4 8 
±112 
±115 
±118 
±122 23 25 27 28 29 ETb36 
±257 
±2
Informed consent X
Admission to CRU X X X
Drug and a lcohol screen Xs
Discharge from CRU c X X X
Outpatient visits to CRU X X X X X X X
Distribution of glucose 
meters, test strips, and 
diaries /SMBG trainingXd X X X X
Administer study drug e X X X X
Phone calls for safety/
immune monitoringX X
Medical history X
Height and weight f X Predose Predose Predose Predose X X
Physical examination X
Medical assessment t X Predose XPredose Predose Predose X X X X
Hemoglobin A1C g,h X Predose X X
Vital signs (BP/PR) i,j
(hr)X XPredose, 
1, 4, 8, 
and 12X X X X X X X X X X X
ECG j,k(hr) XPredose, 
8X X X PredosePredose , 
8X X X X X X
PK sampling l(hr)Predose , 
8X X X XPredose , 
8X X X X X X
Body temperature X X X X
Clinical safety labm X X X X X X X X X X X X
Glucose only (hr) n 8 8 X X
AEs/concomitant 
medicationsX X X X X X X X X X X X X X
7-point glucose profile X X X X X
OGTT o X X X
I8F-MC-GPGA(f) Clinical Pharmacology Protoco l Page 15
LY3298176Procedure Screen aPrestudy Baseline Treatment a Follow -up
Days Before 
Day −2−2 −1 1 2 3 4 8 
±112 
±115 
±118 
±122 23 25 27 28 29 ETb36 
±257 
±2
Acetaminophen test for 
gastric empty ingpX X X
Lipid panel q Predose X X
Adiponectin q Predose Predose X
Cortisol q Predose Predose X
Bone markers:  P1NP, 
osteocalcin, CTX -1g,hPredose X X
Pharmacogenomic 
sampleX
Nonpharmacogenetic 
sampling (storage) rPredose Predose Predose Predose X X
Immunogenicity X X X X X X X X
Abbreviations:  AE = adverse event; BP=blood pressure; CRU =clinical research u nit;CTX-1 = carboxy -terminal telopeptide fragments of Type I collagen; 
ECG = electrocardiogram; ET= early termination; lab =laboratory ; OGTT =oral glucose tolerance test ; P1NP = N -terminal propeptide of Type I collagen; 
PK = pharmacokinetic ; PR =pulse rate ;SMBG =self-monitored blood glucose; T2DM = type 2 diabetes mellitus .
aScreening shall be completed up to 28 days before study  enrollment .  For Part C, the screening period will be longer for patients with T2DM treated with 
sulfon ylureas; these patients will be required to stop their treatment and have a 6 -week washout period before dosing with study drug.  Clinical tests will be 
repeated if dosing would be >28 days from initial screening.
bFor early  termination, the patient /subject will complete D ay 29 pre dose time frame pharmacodynamic , PK, and safety lab oratorycollections and a single ECG 
and vital signs measurement if during the treatment period, and Day 57 procedures if during the follow -up.  Patients /subjects who are discontinued early from 
the study  will be asked to complete a follow -up visit with Day 57 procedures aft er a washout period of at least 28 days from the last dose of study drug.
cFor the initial CRU admission, p atients must remain at the CRU at least until the morning of Day 4.
dPatients with T2DM (Part C) who were taking sulfonylureas at screening will b e required to monitor their glucose during the 6 -week washout period.
eStudy drug will be administered after an overnight fast of at least 8 hours .
fHeight measured at screening only.  Weight will be measured in a consistent way ,alway s predose.  Scale needs to be calibrated (refer to Section 9.4.3.1 ).
gPart C only.
hPatients will be required to fast for at least 8 hours b efore each blood sample is drawn .
iVital signs sampling:  Day 1:  predose ,and1, 4, 8, and 12 h ours; Days -1, 2, 3, 4, 8, 15, 22, 25 , 29, and 37 at a time matched to predose; andfollow -up,
Days 37 and 57 .  Triplicate measurements will be done in Part C only (patients with T2DM ).
jECGs and vital signs should be scheduled before, but as close as possible to, the PK sample times.  Scheduled meals should oc cur after ECG/vital signs 
measurement.
I8F-MC-GPGA(f) Clinical Pharmacology Protoco l Page 16
LY3298176kA single local safety ECG will be measured at screening and D ay 57(follow -up) or ET visit ; tripl icate ECGs will be measured at predose and 8 hours after 
dose administration on Day s 1and 22 andon Days 2, 3, 4, 8, 23, 25, 29 ,and 36at a time matched to predose.   The Day 1predose ECG will b e taken in 
triplicates every 15 minutes for 1 hour to establish a baseline.  ECGs must be recorded before collecting any blood for safety or PK samples and close to the 
time of the blood draw.   Patients/subjects must be supine for approximately 5 to 10 minutes before ECG collect ion and remain supine but awake during ECG 
collection.
lPK sampling for LY3298176 on Day 1 at predose , 8,and 24 (Day  2) hours postdose, and approximately 48(Day  3), 72(Day 4) , and 168(Day 8) hours after
the first dose (168 -hoursample to be collected before the second dose of LY3298176 ); additional PK samples to be collected at Week 4 after the fourth dose 
(Day  22) at predose, 8, and 24(Day 23) hours postdose , and approximately 72(Day  25)and168(Day  29)hours postdose , and at the follow -
up visits o n 
Day 36 and Day  57.
mClinical safety laboratory measures include chemistry, hematology, and urinalysis panels.  Blood samples will be taken predos e on all dosing days.  Patients 
will be required to fast for at least 8 hours before each blood sample is dr awn.
nNonfasting g lucose samples will be taken with triplicate ECGs and PK time points on the days and/or time points that no clinical safety laboratory samples 
are taken.
oOGTT (insulin and glucose) sampling schedule:  Pre
-glucose dose (75 g) and0.5, 1, 1.5,and 2 hours post glucose dose .  Patients /subjects will be required to 
fast for at least 8 hours before OGTTs.
pAcetaminophen PK sampling schedule:  Pre-acetaminophen dose and0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24 hours post acetaminophen dose.  For the second 
CRU admission, D22, subjects may be discharged on Day 23 or Day 24 after the 24 h ours acetaminophen sample is collected.
qPatients/s ubjects will be required to fast for at least 8 hours before each blood sample is drawn for lipid panel , adiponectin , and cortisol .  Lipid panel includes 
high-density lipoprotein cholesterol, low -density  lipoprotein cholesterol , total cholesterol ,and triglycerides.   Trigly ceride and total cholesterol concentrations 
in the safety panel will not be required on the days that the lipid panel is performed.
rNonpharmacogenetic samples will be collected predose and while fasting for at least 8 hours before each blood sample is drawn .
sPerformed only at site(s) located in the United S tates,and pr ocedures may be repeated throughout the study as deemed necessar y by the investigator.
tAssessment sof injection site rea ctions will be included in the medical a ssessments.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 17
LY32981763.Introduction
3.1. Study Rationale
LY3298176 is  glucose -dependent insulinotropic polypept ide (GIP) and glucagon -like 
pepti de-1 (GLP -1)receptor coagonist being develo ped as a weekly treatment for type 2 diabetes 
mellitus (T2DM) . This first-in-human study  of LY3298176 , I8F -MC-GPGA (GPGA), will 
investigate the safet y, tolerabilit y, pharm acokinetics (PK), and pharmacodynamics (PD) of 
LY3298176 administered as subcutaneous ( SC)injections i n healt hy subjects and in patients 
with T2DM .
3.2. Back ground
In norm al physi ology, the incret ins GLP -1 and GIP are secreted from enteroendocrine cells in 
the gut following a meal to enhance the physio logical  responses to food intake including 
sensat ion of sat iety, insulin secretion, and nutrient disposal.  It is now well known that T2DM 
patients have impaired incret in responses (Nauck et al. 2004) and pharmaco logic interventi ons 
provi ding eit her GLP -1 receptor agonistic peptides or dipeptidyl pept idase ( DPP)-IV inhibitors 
(which delay degradat ion of endogenous GIP and GLP -1) are successfully used in the treatment 
of T2DM (Drucker and Nauck 2006; Amori et al. 2007; Baynes 2010).   Although GLP -1 is 
regarded as the incret in of therapeutic ut ility, published data dem onstrate dthat overexpressio n of 
GIP may lead to improved body weight and glycemic control and the combinat ion of GLP -1 and 
GIP m ay resul t in improved glycemic efficacy and weight management compared with GLP -1 
agonists alone in T2DM patients (Kim  et al . 2012; Finan et al. 2013).
 
 By co mbining 
the 2incret in pharmaco logies, improved glycemic control may be expected based on potential 
additive or synergist ic effects on glycemic and weight benefit s (Irwin et al. 2009).
LY3298 176is intended for the treatment of T2DM as an adjunct to diet, exercise, and oral 
medicat ions.
Based on nonclinical PK data, LY3298176 PK is expected to be linear and dose proportional.  A
half-life of 3 to 5 days in humans is projected
, supporti ng the desired once weekly  dosing 
regimen with <2-fold in peak to trough ratio and accumulat ion at steady -state wi thin 2 to 
4weeks .  The time to maximum concentration ( Tmax) is predicted to be approximately 24hours 
after anSC dose administration.
In vivo safet y pharm acology assessments conducted in accordance with Internat ional Conference 
on Harmonisat ion (ICH) S6 guidelines using LY3298176 did not reveal any substant ive clinical 
risk to the central nervous system, respiratory  system , or cardi ovasc ular f unction in cyno molgus 
monkeys.  Consistent with GLP -1 pharmaco logypreviously observed in nonclinical studies wit h 
this drug cl ass(Goodwill et al. 2014) , effects of LY3298176 on the cardiovascular system in 
monkeys were increased blood pressure and heart rate and decreased cardiac contractilit y.  There 
CCI
CCI
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 18
LY3298176were no effects on QT corrected for heart rate (QTc) at any  dose in monkeys given a single dose 
or after repeated doses in the 1 -month toxi cology study . No adverse effects on neurobehavior or 
respi ratory function were observed.  Cardiovascular funct ion will be monitored in the clinical 
trial.
One-month studies were conducted in rat and cynomo lgus mo nkey.  All of the effects in both 
species were consistent with GLP -1 pharmaco logyand no target organ toxicit y was ident ified.  
In the rat study , effects were limited to decreased food consumpt ion and body  weights.  No 
clinical patho logy effects considered toxico logically  important were observed and there were no 
LY3298176 -related hist opathol ogy findings.  The top dose of 1.5 mg/kg was the no -observed -
adverse -effect level (NOAEL) in rats.  In monkeys, effects included body  weight l oss and
decreased food consumpt ionat ≥0.15 mg/kg and thin clinical condit ionat 0.5 mg/kg .  One 
monkey given the high dose of 0.5 mg/kg required veterinary treatment (supplemental fluids) 
due to decreased food consumpt ion, body  weight loss, and clinical condit ion.  No adverse 
histopathology  effects were noted at any  dose.  Due to the need for veterinarian inte rvent ion 
(administration o f SC fluids) at 0.5 mg/kg, the NOAEL in mo nkeys was 0.15 mg/kg.
Preliminary draft safet y and tol erabilit y data:
In Part A (single- ascending dose [ SAD ]portion)of this study ,more than 50 heal thy subjects 
received study  drug with doses of LY3298176 ranging from 0.25 mgto 8mg.Single d oses of 
study  drug were generally  well tolerated .  Gastrointestinal ( GI)events (loss of appet ite, bloating, 
nausea, vo miting, etc .)were the most comm only reported adverse events ( AEs).  Atthe 8-mg 
dose l evel, 
the majority ofsubjects exp erienced drug -related GI events   Two of the subjects who 
received 8 mg reported AEs of nausea and vo miting that required treatment with ant iemetics and 
intravenous fluids. Further dose escalat ion was therefore stopped.
In Part B ( multip le-ascending dose [MAD ]porti on) of this study , more than30 healt hy subjects 
have been dosed incohorts of 4 weekly  SCfixed doses of 0.5 mg, 1.5 mg, and 4.5 m g; and an 
additional titration regimen cohort of 5 mg for 2 doses ( Weeks 1 and 2), 8 mg (Week 3), and 
10mg (Week4).  
Similar to Part A, the most commo nly reported AEs have been GI events, 
including loss of appet ite, nausea, bloat ing, heartburn, and vo miting. Amajo rityof the AEs have 
been reported following the first week of dosing ,with fewer AEs being reported after the third 
and fourth dose s. The 8-mg dose was better tolerated in this titration approach ascompared with
the single 8 -mg dose evaluated in Part A The limit s of tol erabili ty were not reached in the 
multiple-dose escalation in healthy subjects.
Part C of this study  is current ly ongo ing. Agroup of T2DM pati
ents hasreceived a fixed dose of 
5 mg for 4weeks .GI events were the most comm only reported adverse events in these patients . 
LY3298176 appears to be better tolerated by  T2DM pati ents who received 5 mg doses compared 
to healt hy subjects who received 4.5 mg in Part B of the study .A second group of T2DM 
patients iscurrently being evaluated in Part C using a titration approach with a dosi ng sch eme o f 
5 mg ( Week 1), 5 m g (Week 2), 10 m g (Week 3) ,and 10 m g (Week 4). GI events (decreased or 
loss of appet ite, feeling bloated, nausea, vo miting, etc ) have been reported following the first 
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 19
LY3298176two doses of 5 mg . Preliminary  data regarding the 10 m g dose indicates that LY 3298176 appears 
to be tol erated in this titration approach .
3.3. Benefit/Risk Assessment
The nonclinical safet y informat ion for LY3298176 adequately supports the transit ion from 
preclinical status to a clinical devel opment .  On the basis o f the nonclinical data, LY3298176 is 
not consi dered to be a high -risk com pound.  LY3298176 has not been administered to humans 
previously, and to mit igate this ri sk, the study  has been desi gned to be conducted in accordance 
with principles outlined in the European Medicines Agency ( EMEA 2007) Guideline on 
strategi es to identify and mitigate risks for first-in-human clinical trials wi th investigational 
medici nal products.  Any identified risks are considered to be monitorable and manageable at the 
planned dose range for LY3298176 in healt hy subjects and patients with T2DM .
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated adverse events (AEs) of LY3298176 are to be found in the 
Invest igator’s Brochure (IB ).  
Known and expected benefit s and risks o f dulaglut ide may be
found in the package insert for dulaglutide (Trulicity  package insert, 2015).
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 20
LY32981764.Objectives and Endpoints
Table GPGA. 4.1shows the object ives and endpo ints of the study .
Table GPGA .
4.1 Objectives and Endpoints
Primary Objective Endpoints
To investigate the safety and tolerability following
single and multiple SCdoses of LY3298176 
administered to healthy subjects and patients with 
T2DMAdverse event and safety glucose monitoring .
Secondary Objectives Endpoints
To characterize the PK of LY3298176 following SC 
doses of LY3298176 in healthy  subjects and patients 
with T2DMBlood samples will be evaluated for LY3298176 
concentration for the assessment of LY3298176 PK 
parameters using a noncompartmental method of 
analy sis.
To investigate thePD effects of LY3298176 following 
multiple SC doses of LY3298176 administered to 
healthy  subjectsGlycemic control (including fasting glucose; glucose 
and insulin during an OGTT), gastric emptying using 
acetaminophen, weight, lipids, adiponectin, blood urea 
nitrogen, and cortiso l.
To investigate the PD effects of LY3298176 following 
multiple SC doses of LY3298176 administered to 
patients with T2DMGlycemic control (including fasting glucose; glucose 
insulin during an OGTT , and hemoglobin A1C ), gastric 
empty ing using acetaminophe n, weight, lipids , 
adipo nectin, blood urea nitrogen, and cortisol .
Exploratory Objective Endpoints
To investigate LY3298176 effects on markers of bone 
metabolism (formation and resorption) following 
multiple SC doses of LY3298176 administered to 
patients with T2DMMarkers include:  P1NP, osteocalcin, CTX -1.
Abbreviations:  AUC =area under the concentration versus time curve; CT X-1 = carboxy -terminal telopeptide 
fragments of Type I collagen; ECG =electrocardiogram; OGTT =oral glucose tolerance test; P1 NP= N-terminal 
propeptide of Type I collagen; PD =pharmacodynamic; PK =pharmacokinetic; SC =subcutaneous; 
T2DM = type 2 diabetes mellitus.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 21
LY32981765.Study  Design
5.1. OverallDesign
Study  GPGA is a Phase 1, multiple-site, pati ent-/subject -and invest igator -blind, pla cebo -
controlled, randomized, parallel- dose group, single -ascending dose (SAD ; Part A) ,and a 4-week
multiple-ascending dose (MAD ; Part B) study in healthy subjects, and a 4-week m ultiple-dose 
evaluat ion in pat ients with T2DM (Part C) .  Part B will evaluate Trulicit y®(dulagl utide)as a 
positive control for PD of GLP -1 pharmaco logy.
The pl anned LY3298176 doses for this study  range from 0.25 mgup to 15mg LY3298176
(Secti on5.5).Initially, i t was planned to explore doses up to 10 mg;however, based on a 
preliminary review of safet y,tolerabilit y, and PK data, the upper end of the dose range was 
increased from 10 mgto 15 m g.  Dulaglut idewill be provi ded as a 1.5 -mg SC dose.
Figure GPGA. 5.1illustrates the study  design.
Afollow
-up visit will be perform ed according to the Schedule of Act ivities (Secti on2).
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 22
LY3298176Abbreviations:  Dula =dulaglutide; HV =healthy  volunteers; LY =LY3298176; PL =placebo; T2DM =type 2 diabetes mellitus; 
Wkly =weekly.
This is a general schematic of the study design, but dose levels may be repeated or cohorts added.
Figure GPGA .5.1. General s tudy design for Protocol I8F-MC-GPGA .Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Cohort G:
Cohort F:
Cohort E'
Cohort E:
Cohort D'
Cohort D:
Cohort C'
Cohort C:
Cohort B'
Cohort B: 
Cohort A'
Cohort A:Part B Dose Level 1                     
4 Wkly Doses in HV                    
 (6 LY:1 Dula:1 PL)4 Week Follow UpPart A Dose Level 2
Single Dose in HV (6 LY:2PL)Part A Dose Level 3
Single Dose in HV (6 LY:2PL)                                           Part A Dose Level 4
Single Dose in HV (6 LY:2PL)      
Part B Dose Level 3                     
4 Wkly Doses in HV                     
(6 LY:1 Dula:1 PL)Part A Dose Level 5
Single Dose in HV (6 LY:2PL)     Part A Dose Level 6
Single Dose in HV (6 LY:2PL)
Part B Dose Level 5
4 Wkly Doses in HV
(6 LY:1 Dula:1 PL)4 Week Follow Up
Part B Dose Level 2                     
4 Wkly Doses in HV                     
(6 LY:1 Dula:1 PL)4 Week Follow Up4 Week Follow UpPart B Dose Level 4                      
4 Wkly Doses in HV                     
(6 LY:1 Dula:1 PL)4 Week Follow Up4 Week Follow UpPart C                                                  
4 Weekly Doses in T2DM              
( 8LY1, 8LY2, 4PL)
Part A Dose Level 1
Single Dose in HV (6 LY:2PL)Part A to B interim (safety data cutoff)
Part A to B interim (PK data cutoff)
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 23
LY3298176Patient/s ubject eligibilit y for this study  will be determined at a screening visit.  Eligible 
patients/su bjects will be admitted to the clinical research u nit (CRU) on Day −1(Part A) or on 
Day -2 (Parts B and C) .  If the invest igator decides not to administer the firstdose to a 
patient/ subject or not to enroll a patient/subject on a particular day, the patient/ subject may be 
rescheduled to parti cipate in the same part of the study  and any procedures performed up to that 
point may be repeated.   Alternat ively, the patient/subject may be rescheduled to participate in 
another part of the study  if he/she consents to doing so and meets the inclusio n/exclusio n criteria.
Patients/s ubjects will be given a nSC dose of LY3298176 (or placebo or dul aglut ide) on Day 1 
(Parts A, B, and C) and Days 8, 15, and 22 (Parts B and C only) after an overnight fast (at least 
8hours) .  PKsampling and safet y assessments, including AE , medical assessments ,clinical 
laboratory  tests, vi tal signs, and electrocardiograms (ECGs), will be perform ed according to the 
Schedule of Act ivities(Secti on2).  PK or PD sampling schedules may be modified based on the 
available safet y and PK data.
The invest igator or qualified designee will review all available inpat ient safet y data before 
discharging patients/subjects fro m the CRU on the morning o f Day 4, provi ded they  are deemed 
medically fit by  the invest igator.  Patients/s ubjects may be required to remain at the CRU longer 
than Day 4 at the investi gator’s di scret ion.  Safet y, as assessed by  AEs, clinical safet y laboratory  
tests, vi tal signs, 12 -lead ECGs, concomitant medications, and medical assessments ,will be 
reviewed by the sponsor and invest igator before each dose -escalat ion decisio n.
During the study , pati ents/subjects m ay rem ain at the CRU as needed for safet y follow-up based 
on clinical judgment of the principal invest igator. 
A Safet y Review Panel (SRP) will be esta blished and co mposed of experts in early phase 
medicine independent of the study  team  and investigat ive site. When the study  team  
recommends a dose that differs from that anticipated by the protocol  in Part A, and for the doses 
for Parts B and C, the SRP will review the recommendat ion(s) of the study  team  and provi de a 
recommendat ion in return to the study  team .
Patients/s ubjects will be discharged after the review of all final safet y assessments from the last 
follow-up visit is completed by the invest igator.
5.1.1. Single -Ascending Dose Study in Healthy Subjects (Part A)
Part A will consist of up to 6escalat ing single -dose l evels of LY3298176 orplacebo in healt hy 
subjects.  Approximately 48subjects will be randomized into 6 groups (Cohorts A through F)as 
follows:
Cohort
s Athrough F :  approximately 8subjects per cohort, with a rati o of 
6LY3298176: 2placebo .
Each new dose level will be init iated only if safet y results through Day  8 from at least5subjects 
receiving LY3298176 in the preceding dose level are deem ed acceptable by  the invest igator and 
the Lilly  clinical  pharmacol ogist.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 24
LY32981765.1.2. Multiple -Ascending Dose Study in Healthy Subjects (Part B)
The MAD porti on of  the study  will be initiated after review of safety and PK data from Day 8 of 
the second SAD dose level and safet y data through Day  8 of the thi rd SAD dose l evel.  In Part B, 
approximately  40healt hy subjects in Cohorts Athrough Ewill be administered 4 weekly SC 
doses within the dose and exposure range of the SAD as fo llows:
Cohorts Athrough E:  approximately 8 subjects per cohort ,wit
h a rati o of 
6LY3298176:1 placebo: 1dulaglut ide.
The dose levels in Part B will be determined on the basis o f safet y, tolerabilit y, and PK data from 
Part A.  Dose escalat ions will be based on the evaluation o f preliminary  safety  and tol erabilit y 
data from at least 5 subjects receiving LY3298176 through Day 15 of  the previ ous MAD dose 
level.
Amendment to Parts A and B
The protocol has been amend edto allow the addi tion of up to threecohorts of approximately 
8subjects each.  These additional cohorts m ay be utilized to explore the full single (Part A) or 
multiple (Part B) dose range planned or to evaluate dose ti tration regimens in Part B of the study .
The a dditional cohorts will be assigned the next available letter designation. 
5.1.3. Multiple -Dose Evaluation in Patients with Type 2 Diabetes 
Mellitus (Part C)
Part C of the study  will be a 4 -week m ultiple-dose evaluat ion of LY3298176 in approximately 
20 pati ents wi th T2DM.  Pati ents will be administered 4 weekly SC d oses of LY3298176 or 
placebo in a ratio of 16LY3298176:4 placebo (Cohort G) . Patients receiving LY3298176 will 
be randomized into 1 of 2 different dose levels (8 pati ents per dose level) .  
Dose levelswill be 
determined based on safet y, tolerabilit y, and PD data from  Part B.
Part C m ay be ini tiated based on the evaluat ion of safet y and tolerabilit y data f rom Part B
(MAD ).
Amendment to Part C
The protocol has been amended to allow the addit ion of up to 2cohorts (up to 15 patients each) 
of T2DM pati ents to enable assessment of doses up to 15 mg through dose titration. 
5.2. Number of Participants
Approximately  143 healt hy subjects and up to approximately 55 patients with T2DM may be 
enrolled sothat approximately 112 healthy subjects and up to approximately 40 patients
complete the study .
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on2) for the last patient/subject .
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 25
LY32981765.4. Scientific Rationale for Study Design
Safety and tol erabilit y assessments will be made over all dose l evels .  Although only a m odest 
glucose -lowering effect is expected in healthy subjects due to LY3298176 action on glucose -
dependent insulin secret ion, a preliminary  assessment of the PD effects of LY3298176 will be
based on gastri c empt ying (acetaminophen test) and insulin response f ollowing oral  glucose 
tolerance tests (OGTTs ).
The study  is intended to estimate a maximum -tolerated dose (MTD) or establish that doses 
exceeding the expected therapeutic dose are tolerated.  Preliminary PK, PD, safet y, and 
tolerabilit y data in healt hy subjects and pat ients with T2DM will assist in identifying an 
appropriate dose range for subsequent clinical studies.
To establish a quant itative range for the GLP -1 pharmaco logy, dulaglut idewill be used as a 
positive control  and placebo will also be used as a com parator to allow interpretation o f PD, 
safet y, and tol erabili ty data .
5.5. Justification for Dose
The pl anned doses in this study  are selected to provide a full evaluation of the safet y and 
tolerabilit y of LY3298176 at doses ideally 3-fold beyond the e xpected therapeutic dose range to 
allow characterizat ion of the PK and preliminary assessment of the PD effects of LY3298176 in 
the target patient populat ionover a wi de dose and exposure range to support dose select ion in 
future clinical trials .  The anticipated dose-limit ing safet y and tol erabili ty profile (nau
seaand 
vomiting) of LY3298176 has been consistent ly demo nstrated with the GLP -1 drug class.
Based on PK and PK/ PD m odeling of nonclinical data, the starting dose of 0.25 mg may provide 
detectable L Y3298176 exposure expected to demonstrate minimal to no pharmaco logical 
response in healt hy subjects in Part A (SAD).  Based on the allo metry -based projected human 
exposure, the exposure at the NOAEL from the rat and monkey repeat -dose stud iesis >10 -fold 
margin o f safet y to the starting dose of 0.25 mg (Table GPGA .5.1).   Furthermore, t he starting 
dose of 0.25 mg is predicted to achieve maximum drug concentration (Cmax) of approximately 
4-and 30-foldbelow the inhibitory constant ( Ki)of GIP and GLP -1 huma n receptor binding, 
respectively , based on the in vitro pharmaco logy studi es.  Doses at 1 mg or higher are expected 
to achieve concentration sabove these Ki values.
In Part A of the study , the planned dose l evels to be evaluated are :  0.25 mg, 0.5 mg, 1 mg, 
2.5mg, 5mg,and 10 m g.
The clinical dose range to be studied in Part B (MAD) will be selected based on safet y, 
tolerabilit y, and PK data from Part A (SAD)
.  The starting dose planned for Part B (MAD) is
0.25 m g once weekly  for 4 we eks.  The m aximum  dose planned is 10 mg .  
Doses m ay be adjusted before each dose escalation in both Part A and Part B based on safet y, 
tolerabilit y,and available PK/P Ddata during the course of the study .  Any changes to the 
planned dose l evels, together with the supporting data, will be reviewed by  SRP (refer to 
Secti on5.1).  The doses to be evaluated in Part C in patients with T2DM will be selected based 
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 26
LY3298176on safet y, tolerabilit y, and pharmaco logy from Part s A and B (SAD and MAD) and reviewed by  
the SRP.
The m argin o f safet y for SC administration of LY3298176 is presented in Table GPGA .5.1.
Table GPGA .
5.1. Margin of Safety for Subcutaneous Administration of LY3298176
Based on Body Surface A reaand Predicted Exposure
Dose
(mg/kg)Dose
(mg/m 2)Dose
Multiple to 
Human 
Starting 
DoseDose 
Multiple to 
Human 
Maximum 
Dose aAUC
(µg•hr/mL)Exposure 
Multiple to 
Human 
Starting 
DoseExposure 
Multiple to 
Human 
Maximum 
Dose
Human starting 
dose (0.25 mg)0.0036b 0.132 - - 8.62 - -
Human maximum 
dose(10 mg) b0.143 b 5.29 - - 345 c - -
Rat NOAEL d 1.5 8.85 67 1.67 134 h 27e 0.68 e
Monkey NOAEL f 0.15 1.80 14
0.34 115 i 13g 0.33 g
Abbreviations:  AUC = area under the plasma concentration versus time curve; AUC(0 -96) = AUC from time 0 to 
96 hours; AUC(0 -168) = AUC from time 0 to 168 hours; NOAEL =no-observed -adverse -effect level ; 
PK=pharmacokinetic .
aDose multiple is calculate d as dose in animals (mg/m 2)/dose in humans (mg/m 2).
bTypical body weight of 70 kg was assumed for a healthy subject.
cPlasma PK parameter sshown were computed based on PK model -
predicted LY3298176 concentration -time 
profile. Dose shown is the highest proposed clinical dose .
dNOAEL determined in a 1- month repeat dose toxicity study (Study 8325822).
eExposure multiple is calculated as the ([AUC (0-96) in rats ]/96hr)/([AUC (0-168) in humans ]/168 hr).
fNOAEL determined in a 1
-month repeat dose toxicity s tudy (Study 82325823).
gExpo suremultiple is calculated as the ([AUC(0 -168) in monkeys]/168 hr)/([AUC(0 - 168) in humans]/168 hr).
hAnimal AUC(0 -96) is mean M ale + Female from S tudy 8325822 ,Day29toxicokinetic data.
iAnimal AUC(0 -168) is mean M ale + Female from S tudy 8325823 ,Day29toxicokinetic data.
Protocol Amendment (f)
Healthy subjects were given single doses up to 8 mg near the limits of tolerabilit y in Part A ,and 
4 fixed weekly doses of 0.5 mg, 1.5 mg,and 4.5 mg and up to 10 mg as part of a titration scheme 
in Part B .The limits o f tolerabilit y were not reached in either Part A or B of this study . In 
Part C,LY3298176 was given to patients with T2DM in a fixed 5 -mg weekly dose cohort and a 
titration cohort of 5 m g, 5mg, 10 mg,and10 m g over 4 weekly doses. Based on better 
tolerabilit y ofLY3298176 in T2DM patients compared wi th healt hy subjects and updated
margins of safet y based on human exposure data from Parts A and B of this study  (see 
TableGPGA. 5.2), the protocol is amended to evaluate a maximum dose of LY3298176 up to 15 
mg in T2DM patients as part of up to 2addit ional titration schemes in Part C of this study .
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 27
LY3298176TableGPGA .5.2. Updated Margin of Safety for Subcutaneous Administration of 
LY3298176 Based on Preliminary Human PK Data 
Dose Dose AUC Exposure 
Multiple 
to Human 
Starting 
DoseExposure 
Multiple to 
Human 
Maximum 
Dose(mg/kg) (mg/m 2) (µg•hr/mL)
Human 
maximum dose 
(15mg) b0.214 b 7.92 342 c -
Rat NOAEL d 1.5 8.85 134 h 0.68 e
Monkey 
NOAEL f0.15 1.8 115 i 0.33 g
Footnote: Refer to Table GPGA .5.1.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 28
LY32981766.Study  Population
Eligibilit y of patients/subjects for study  enrollment  will be based on the results of screening 
medical history , physical examinat ion, vital signs, clinical laboratory  tests ,and ECGs.
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening may occur up to 28 day sbefore enrollment. However, the screening period will be 
longer f or pati ents wi th T2DM treated with sulfo nylureas; these patientswill be required to stop 
their treatm ent and have a 6 -week washout period before dosingwith study  drug .
Patients/s ubjects who are not enrolled within 28days of screening m ay be subjected to an 
additional medical  assessment and/or clinical measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Cri teria
Patients/s ubjects are eligible for inclusio n in the study  only if they  meet all of the following 
criteria at screening and/or enrollment:
6.1.1. All Study Participants
[1] are overtly healt hy males or females, as determined by  medical hi story  and 
physical examinat ion(Parts A and B only )or have T2DM diagnosed at least 
1year before enro llment (Part C only)
[1a] male pat ients/subjects:
agree to use an effect ive method of contraception for the duration of the 
study  and for 3 months following the l ast dose of investigational product
[
1b]female patients/subjects:
women not of child bearing potential due to surgical sterilization 
(hysterectomy or bilateral oophorectomy  or tubal  ligat ion) or m enopause.  
Women with an intact uterus are deemed postm enopausal  if they are 
≥45years o ld
AND
who have not taken hormones or oral contraceptives within the last y ear and 
had cessat ionof menses for at l east 1 y ear
OR
who had at least 6 months of amenorrhea with fo llicle -stimulat ing hormone 
levels consist ent wi th a postm enopausal  state
[2] are males or females between the ages of 21 and 70 years, inclusive
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 29
LY3298176[3] have a screening body  mass index of >18.5 and ≤40.0 kg/m 2(healt hy 
subjects) or ≥25kg/m 2(T2DM pati ents) ,inclusive
[4] have clinical laboratory  test resul ts within the normal range for the populat ion 
or investigator site, or with abnormalit ies deemed clinically insignificant by  
the invest igator
[5] have bl ood pressure of <160/90 mm Hgand pulse ra te of 50 to 100 bpm
(supine) at screening, or with minor deviat ions judged to be acceptable by the 
investigator
[6] are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures
[7] have given wri tten informed consent approved by  Lilly and the ethi cal review 
board (ERB) governing the site
[8] have venous access sufficient to allow blood sampling as per the protocol
6.1.2. Patients with T2DM (Part C only)
Patients are eligible for enrol lment i n Part C of the study  only if they  meet all  of the f ollowing 
additional criteria:
[9] have T2DM controlled wit h diet and exercise alone or are stable on a single 
oral antidiabet ic medicat ion (metformin for at least 8 weeks or sulfo nylureas) . 
However, pati ents receiving sulfo nylurea smay participate only if this 
treatm ent is stopped for at least 6 weeks before dosing with study  drug
[10] are taking stable doses ofover-the-counter or prescription medicat ions (for 
example, antihypertensive agents, aspirin, lipid-lowering agents) for treatment 
of concurrent medical condit ions are permitted to participate providing they  
have been stable on thei r treatm ent regimen for at least 4weeks
[11] have an hemoglobin A1c ( HbA1c )≥7.0% and ≤ 11.0%,and for the patients 
who have washed off of sulfo nylureas, HbA1c ≥7.0% and ≤ 8.5%, at the 
screening visit
[12] have abnorm alities of serum glucose, serum lipids, urinary glucose, and 
urinary  protein cons istent with T2DM are acceptable
6.2. Exclusion Criteria
Patients/s ubjects will be excluded fro m study  enro llment if they meet any o f the following 
criteria at screening and/or enrollment:
6.2.1. All Study Participants
[13] are invest igativesite personnel  direct ly affiliated with this study  and thei r 
immediate families.  Immediate family is defined as a spouse, parent, child ,or 
sibling, whether bio logical or legally adopted
[14] are Lilly  empl oyees
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 30
LY3298176[15] are currently enrolled in a clinical  trial involving an invest igational product or 
any other ty pe of medical research ju dged not to be sci entifically or medically 
compatible with this study
[16] have known allerg ies to LY3298176, GLP -1 analog s,or related compounds , 
or acetaminophen (Parts B and C only )
[17] are persons who have previously co mpleted or withdrawn fro m this study
[18] have a significant history  of or current cardi ovascular (for exam ple, 
myocardial  infarct ion, congestive heart failure, cerebrovascular accident, 
venous thromboembolis , etc), respi ratory , hepatic, renal, gastrointestinal ( GI), 
endocrine (except T2DM patients ), hematological (including history  of 
thrombocy topenia), or neurol ogical disorders capable of significant ly altering 
the absorpti on, m etabo lism, or eliminat ion of drugs or of const ituting a risk 
when taking the study  medicat ion or interfering with the interpretation of data
[19] havea history  of heart bl ock or a PR i nterval >200 msec or any abnorm ality in 
the 12-lead ECG at screening that, in the opinio n of the invest igator, increases 
the risks associated with participating in the study
[20] intended use of over -the-counter or prescription medicat ions 7 and 14 days 
before planned dosing (Parts A and B ,respectively )and 4 weeks before 
planned dosing (Part C) , apart from occasi onal intake of vitamin/mineral 
supplements, allowable ant iemetics, a nd acetaminophen 14 days before the 
first dose .  If this situat ion arises, inclusion o f an otherwi se suitable 
patient/ subject may be at the discret ion of the investigator (refer to
Secti on7.7)
[21] have a history  of drug or alcohol abuse
[22] evidence of hepatit is Bor posit ive hepat itis B surface ant igen and/or evidence 
of hepati tis Cor hepatit is C ant ibody (United States [ US]only)(at screening)
[23] evidence of human immunodeficiency  virus (HIV) and/or posi tive HIV 
antibodies (at screening)
[24] blood donati on of  450 mL or m ore in the l ast 3 m onths or any  blood donati on 
within the last m onth from screening
[25] have an average weekly  alcohol  intake that exceeds 21 units per week (males) 
or 14 uni ts per week (females) ( 1 uni t = 12 oz or 360 mL of beer; 5 oz or 
150mL of wine; 1.5 o z or 45 mL of dist illed spirit s), or patients/ subjects 
unwilling to stop alcoho l consumption 24 hours before dosing unt il discharge 
from the CRU
[26] smoke >10 ci garettes per day  or the equivalent or are unable or unwilling to 
refrain fro m nicotine during CRU admissio n
[27] have received treatment with a drug that has not received regulatory  approval  
for any  indicati on within 30 days of screening
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 31
LY3298176[28] have a history  or presence of pancreat itis (history of chronic pancreat itis or 
idiopathic acute pancreat itis), elevat ion in serum amylase or lipase (> 1.5-fold 
the upper limit of normal [ULN]) or GIdisorder (for example, re levant 
esophageal reflux or gall bladder disease) or any  GIdisease which impacts 
gastri c empt ying (for example, gastric bypass surgery, pyloric stenosis, with 
the except ion of appendectomy) or could be aggravated by  GLP -1 analogs or 
DPP-IVinhibitors.  Pa tients wi th dyslipidemia, and patients who had 
cholecysto lithiasis (removal of gall stones) and/or cho lecystectomy (remo val 
of gall bladder) in the past, with no further sequelae, may be included in the 
study  at the di screti on of  the invest igator
[29] havea history  of atopy  or clinically  significant m ultiple or severe drug 
allergies, intolerance to topical corticosteroi ds, or severe post treatm ent 
hypersensit ivity react ions (including, but not limited to, erythema mult iforme 
major, linear immunoglobulin A dermatosis, toxi c epi dermal  necrolysis, or 
exfoliative dermat itis)
[30] have evidence of significant active neuropsy chiatric di sease as determined by 
the invest igator
[31] have a personal or family history  of medullary  thyroi d carcino ma or have 
multiple end ocrine n eoplasia syndro me type 2
[32] are deem ed unsui table by the invest igator for any other reason
[38] have s erum  aspartate aminotransferase (AST) or alanine aminotransferase 
(ALT) >2x the ULN or total  bilirubin >1.5x ULN
[39] have a h istory  of malign ancy wi thin five y ears pri or to screening
[40] have serum  triglyceride (TG) ≥5 mmo l/L(442.5 m g/dL) at screening 
6.2.2. Patients with T2DM (Part C only)
Patients will be excluded fro m study  enro llment if they  meet any  of the fo llowing additional 
criteria:
[33] have taken any  glucose -lowering medicat ions other than metformin and or 
sulfo nylureas (refer to inclusio n criterion [9]) ,including insulin ,in the past 
3months before screening
[34] have had m ore than 1 epi sode of severe hypoglycemia, as defined by the 
American Diabetes Associ ationcriteria, wi thin 6 m onths before entry  into the 
study or has a history  of hypoglycemia unawareness or poor recognition of 
hypoglycemic symptoms.  Any patient that cannot communicate an 
understanding of hypoglycemic symptoms and the appropriate treatment of 
hypoglycemia prior to the first dose of study  drug shoul d also be excluded
[35] impaired renal funct ion (serum creat inine >124 µmol/L [1.4 mg/dL] in
wom en, >133 µmol/L [1.5 m g/dL] in men, or estimated gl omerul ar fil tration 
rate[eGFR] <60 mL/min/1.73 m 2)in patients wi thT2DM on metformin
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 32
LY3298176[36] have had a blood transfusio n or severe blood loss or have known 
hemoglo binopathy (alpha -thalassemia ), hem olytic anemia, sickle cell anemia, 
or have a hemoglo bin value <11g/dL (m ales) or < 10g/dL (females), or any 
other condit ion known to i nterfere wi th HbA1c methodol ogy
[37] have received chronic (last ing >14 consecut ive days) systemic glucocortico id 
therapy  (excluding topi cal, intra -articular, and inhaled preparati ons) in the 
past y earorhave received any glucocortico id therapy within 30 days before
screening
6.3. Lifestyle and/or Dietary Requirements
Throughout the study, patients/subjects undergo medical assessments and review of compliance 
with requi rements b efore continuing in the study .
6.3.1. M eals and Dietary Restrictions
Patients/subjects will be requi red to fast overnight for at least 8 hours before taking a SC dose of 
LY3298176 (or placebo) onDay 1(Part A) and Days 1, 8, 15, and 22 (Parts B and C) ,and for 
each subsequent study  day whe nclinical safet y laboratory and PD samples are taken and OGTT s
are administered .  Water may be consumed freely.   Standard meals will be administered in the 
CRU.
6.3.2. Caffeine, Alcohol, and Tobacco
No al coho l will be allowed at least 24 hours before each CRU admissi onand each outpatient 
visit and throughout the duration o f each CRU visit.  Between CRU visit s, daily  alcohol  shoul d 
not exceed 3 units for males and 2 units for females (a unit is defined in Exclusio n Cri terion [25], 
Secti on6.2.1 ).  No nicotine use will  be permitted while at the CRU.   
While not resident in the 
CRU, pati ents/subjects m ust consum e no m ore than 10 cigarettes or equivalent per day .
Patients/s ubjects will be allowed to maintain their regular caffeine consumpt ion throughout the 
study  period.
6.3.3. Activity
Patients/s ubjects will be advised to maintain their regular levels of physical act ivity/exercise 
during the study . When certain study  procedures are in progre ss at the site, patients/ subjects m ay 
be required to remain recumbent or sitting.
6.4. Screen Failures
Subjects who do not meet the criteria for participatio n in this study  (screen failure) m ay not be 
rescreened ;however ,T2DM patients in Part C may be rescreened once .  The interval between 
rescreenings should be at least 2 weeks.  Each time rescreening is performed, the patientmust 
sign a new informed consent form (ICF) and will be assigned a new ident ification number.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 33
LY32981767.Treatment
7.1. Treatment Administ ered
 
  Doses will be dispensed in accordance with the rando mizat ion scheme provided 
by the sponsor.  Patients/s ubjects assigned to placebo treatment will receive SC injec tions of  
norm al saline with the vo lume matching the investigat ional drug at each dose level.   Please refer 
to the pharmacy binder for detailed instructions.
Dulaglut ide will be provided as a 1.5 -mg/0.5 -mL single -use pen.  Dulagl utide will beinjected 
subcutaneously into the abdo men.
All injecti ons will be administered into the SC tissue of the abdom inalwall.  Inject ion sites will 
be alternated weekly between 4 sites (that is, right and left upper quadrants and right and left 
lower quadrants) on the abdo minal wall.
Whenever possible, study  drug administrati on shoul d be carri ed out by  the sam e personnel.  
Dosing will co mmence at approximately the same time of day in all dose cohorts.  The actual 
time of dosing will be recorded in the patient’s/ subject’s case report form (CRF).
The invest igator or designee is responsible for:
explaining the correct use of the investigational product(s) to the patient/subject/site 
personnel ,
verifying that instructions are fo llowed properly ,
maintaining accurate r ecords of investigational product dispensing and co llection
,
returning all unused medication to Lilly  or its designee at the end of the study .
Note : In some cases, sites may destroy  the m aterial  if during the invest igative site select ion the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical trial materials.
7.1.1. Packaging and Labeling
Materi als for thi s study  are as foll ows:
LY3298176 will be provi dedin a vial and provided in a carton.
Placebo will be provi dedas sodi um chl oride (saline) in a vial .
Dulaglut ide will be provi dedin a carton with 4 single -dose pens per carton.
Clinical trial materials will be labeled according to the country ’s regul atory  requi rements.
CCI
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 34
LY32981767.2. Method of Treatment Assignment
For Parts A and B, r ando mizat ion tables for allocatio n of LY3298176 , dulaglut ide,or placebo 
will be prepared by the statist ician for the study and provi ded to the si te pharm acists involved in 
dose preparation.   For Part C, patients will be assi gned to LY3298176 or placebo by a 
computer -generated
,randomized sequence using an interactive web response system (IWRS).
The allocation and dispensing o f the invest igational products will be fully documented and 
verified by a second person. Detailed re cords of the amounts of the invest igational product 
received, dispensed, and remaining at the end of the study will be maintained by the site 
pharmacist.
7.2.1. Selection and Timing of Doses
The doses will be administered in the morning at approximately  the same times on each day .  
The actual  time of all dose administrations will be recorded in the patient’s/subject ’s CRF.
7.3. Blinding
For LY 3298176 and placebo, the dosing is a patient-/subject -and invest igator -blind.  
Dulaglut idedosing will be open -label.  To preserve the blinding of the study for LY 3298176 and 
placebo , all study  site personnel, except pharm acy staff who prepare and dispense study  
medicat ion, will be blinded to treatment allocat ion.
Blinding of LY3298176 and placebo will be maint ained throughou t the conduct of the trial until 
all data are cleaned to an acceptable level o f qualit y and l ocked .  The details are included in the 
blinding/unblinding plan .
The site pharmacist who prepares and dispenses study  medicat ion will receive a rando mizat ion 
tablefor Parts A and B, and use of an IWRS for Part C, with treatm ent codes to enable 
preparati on of  blinded placebo doses. The pharmacist will assign treatment.
If a patient ’s/subject’s study  treatm ent assignment (LY3298176 or placebo) is unblinded, the 
patient/subject must be discont inued fro m the study unless the invest igator obtains specific 
approval  from a Lilly  clinical  pharmacol ogist or clinical research physician for the study  
participant to continue in the study .
For Parts A and B, e mergency codes wi ll be available to the invest igator.  A code, which reveals 
the treatment group for a specific study  patient/ subject, m ay be opened during the study  only  if 
the patient’s/subject’s well-being requires knowledge of the patient’s/subject’s treatment 
assignme nt.For Part C, unblinding o f study  drug treatm ent will be conducted through the use of 
an IWRS. Site personnel will be able to unblind patient treatment at any  time using the IWRS.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a patient’s/subject ’streatm ent assi gnment i s warranted for m edical management of the event.  
Patient’s/subject ’ssafety  must al ways be the first consideration in making such a determinat ion.  
If the invest igator decides that unblinding is warranted, the invest igator should make every effort 
to con tact the Lilly  clinical  pharmacol ogist or clinical  research physician before unblinding a 
study  patient’s/subject ’s treatment assignment unless this could delay emergency treatment o f 
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 35
LY3298176the pati ent/subject .  If a study  patient’s/subject ’s treatment assignment is unblinded, Lilly must 
be notified immediately.
Upon com pletion of the study , all codes m ust be returned to Lilly  or its designee.
7.4. Dose Modification
Dose l evels or increm ents, sampling schedule, and length of CRU stay  may be adj usted in view 
of emerging safet y or PK data during the study .  Dose increments may be reduced (but not 
increased), a dose level may be repeated, or a lower dose may be administered.  Dose escalations
will not exceed a half-log (3.3 -fold) increase in dose .  The timing of the sampling may be 
adjusted, but the number of samples will not increase.  The duration of the CRU stay  or the 
durati on of  safet y follow-up m ay be increased (for example, if the half -life of LY3298176 is 
longer than ant icipated) but not decreased.  These changes must be appropriately documented 
and co mmunicated by the sponsor to the invest igator.  Because these adjust ments to timings or 
dose l evels are allowable changes permitted by  the proto col, they  woul d not requi re a protocol  
amendment.   However, any changes to the planned dose levels, together with the supporting 
data, will be reviewed by an SRP (refer to Section 5.1).
There will not be any  dose m odificat ions of dulaglutide.
7.5. Preparation/Handling/Storage/Accountability
All clinical trial material provided to the invest igator will be stored in a secure place and 
allocated and dispensed by appropriately trained persons.  The allocat ion and dispensing of the 
investigat ional products will be fully  documented and verified by  a second person.  Detailed 
records of the amounts of the invest igational product received, dispensed, and re maining at the 
end of the study  will be m aintained.
Only participants enro lled in the study  may receive invest igational product and only authorized 
site staff may supply or administer study  treatm ent. All study  treatm ents shoul d be stored i n an
environmentally  controlled and mo nitored (m anual or autom ated) area in accordance with the 
labeled storage condit ions with access limited to th e invest igator and authorized site staff .
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance ( such as
recei pt, reconciliat ion,and final disposit ion records) .
7.6. Treatment Compliance
The invest igational product will be administered at the clin ical site and documentation of 
treatm ent administration will occur at the site.
Every  attem pt will be m ade to sel ect patients/subjects who have the abilit y to understand and 
comply with instructi ons. No doses can be missed. Noncom pliant patients/subjects may be 
discontinued fro m the study and may  be replaced upon consultation with Lilly  clinical  
pharmaco logist.The time and day of drug administration will be recorded.  Drug accountabilit y 
records will be maintained by the study  site.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 36
LY3298176The specificat ions in this protocol for the timings of safet y, PK, and PD sampling are given as 
targets and are to be achieved within reasonable limits.  Modificat ions may be made to the time 
points based upon the safety  and PK informat ion obtained.  The scheduled time points may be 
subject to minor alterations; however, the actual time must be correctly recorded in the CRF.
Failure to obtain samples due to clinical issues, such as problems wit h venous access or the 
patient/ subject does not show up for a visit , will not be con sidered protocol vio lations.  However, 
the site will st ill be required to notify  the sponsor in wri ting to account for missing samples for 
data reconciliat ion purpose.
Any major m odificat ions that might affect the conduct of the study , patient/ subject safe ty, and/or 
data integrit y will be detailed in a protocol amendment.
7.6.1. Dose Decision/Escalation
By nature of being a dose -escalat ion study , data will be evaluated on an ongoing basis unt il the 
MTD is determined or stopping criteria have been met.
Safety data will be the primary  criteria f or the dose escalation.  In addit ion, if available at the 
time of dose escalat ion decisio n, PK or PD results will be used as supporting data for dose 
escalat ion, but such data are not required.  No dose escalation can occur wi thout pri or discussi on 
and agreement between the invest igator and the Lilly clinical pharmaco logist.
Safety data, in particular, AEs, SAEs, and adverse laboratory  abnorm alities, will be 
independent ly assessed by the invest igator and will be considered rela ted to the invest igational 
product unless there is clear evidence that the event is not related.
After review of these data, escalat ion to the next dose level will be made by the invest igator and 
sponsor.  The magnitude of the dose escalat ion may be reduce d(as low as 2 -fold from the 
previous dose) following data revi ew, but subsequent escalations cannot be increased by more 
than approximately 3 -fold (a half -log increment) or dose levels may be repeated.
Based on tolerabilit y data, a dose -titration regimen may be evaluated in Part B or C.
The dose escalat ion and further dosing at the same dose level will be terminated if 
1treatm ent-related SAE (unl ess due to anti cipated pharmaco logy of LY3298176, for example, 
hypoglycemia in healt hy subjects or T2DM) o r 2clinically  significant events (CSEs) are 
reported or; ≥40% of patients/subjects in a dose level experience a symptomatic hypoglycemic 
episode with blood glucose values ≤2.8 mmo l/L (50 mg/dL; corresponding to plasma glucose 
levels o f ≤3.1 mmo l/L [56 m g/dL]) andthese events are deem ed to be rel ated to LY3298176
administration occur.
Addit ionally , the dose -escalation and further dosing at the same dose level will be terminated if 
≥2 subjects experience an acute pancreatit is event as defined in Appendix 5 .
Examples of unrelated events could include but ar e not limit ed to: events occurring before 
LY3298176 dosing ;events experienced after receiving placebo ;personal injury  accidents that
were not a result of hemodynamic changes or neurological symptoms (dizziness, visual
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 37
LY3298176disturbance, numbness, loss of muscle control );events resul ting fro m viral or bacterial
infect ions;or changes in clinical chemistry  or liver enzymes as a result of documented acute 
viral hepat itis, alcoho l,or other hepatotoxic drug use.
Appendix 7 presents examples of AEs that are r easonably ant icipated due to disease state and 
may not be considered related to LY3298176.
A CSE will be determined by the investigator or suitable designee (Appendix 4 ) and m ay include 
findings that do not fulfill the criteria for SAEs.  Patients/subjects experiencing CSEs thought to 
be related to the study  drug will  be encouraged to com plete a 28 -day follow-up peri od before 
study  discharge.
Dosing may continue, if deemed appropriate by the invest igator, at doses lower than those 
resul ting in terminat ion of the escalation.
7.7. Concomitant Therapy
Patients/subjects on stabl e conco mitant m edicat ion at the time of study  entry  shoul d continue 
their regul ar, unchanged dose throughout the study.
If the need for new or changes to concomitant medicat ion arises, inclusio n or continuat ion of the 
patient may  be at the di scret ion of the invest igator , preferably after consul tation wi th a Lilly  
clinical pharmaco logist or clinical research physician.   Stable doses (refer to Section 6) of 
over-the
-counter or prescript ion medications (for example, ant ihypertensive agents, aspirin, 
lipid-lowering agents) for treatment of concurrent medical condit ions are allowed.
No start of new concomitant therapy , apart from  occasi onal intake of  vitamin/mineral  
supplements, allowable ant iemetics, and acetaminophen, will be permitted for 14 day s before the 
first dose of LY3298176 through the final poststudy  follow-up visit.  In th e case of mild 
intercurrent illness during the study , concomitant treatment with paracetamo l/acetaminophen 
may be allowed at the discretion of the invest igator. This will be recorded in the CRF.  
However, acetaminophen should not be allowed after midnight and throughout the rest of the day  
on the day  of the gastri c-emptying test.  Additional concomitant medicat ions for treatm ent of 
T2DM are not permitted during the study .
Addit ional drugs are to be avo ided during the study unless required to treat an AE or for the 
treatm ent of an ongoing medical problem.  Any drug given for the treatment of an AE should be 
docum ented as such.
7.8. Treatment after the End of the Study
LY3298176 will not be made available to patients /subjects after concl usion of the study .
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 38
LY32981768.Discont inuation Criteria
8.1. Discontinuation from Study Treatment
Discontinuati on of  the invest igational product for abnormal pancreatic tests should be 
considered by the investigator when a patient/subject meets the fo llowing condi tion:
lipase and /or amylase are con firmed to be ≥3XULN . Please refer to al gorithm for 
the monitoring of pancreat ic events in Appendix 5 .
The cri teria for enrollment m ust be fo llowed explici tly.  If a pati ent/subject who does not meet 
enrollment criteria is inadvertent ly enro lled, that patient /subject is discont inued fro m the 
investigat ional product but may be allowed to continue in the study  to provi de the foll ow-up 
data.
Patients/s ubjects who discont inue the invest igational product early  will have procedures 
perform ed as shown in the Schedule of Act ivities(Secti on2).
8.1.1. Discontinuation of Inadvertently Enrolled Patients/Subjects
If the sponsor or invest igator ident ifies a pati ent/subject who did not meet enrollment crite ria and 
was inadvertently enrolled, a discussio n must occur between the Lilly clinical pharmaco logist
and the invest igator to determine if the patient may continue in the study.  If both agree it is 
medically appropriate to continue, the invest igator must obtain documented approval fro m the 
Lilly clinical pharmaco logistto allow the inadvertent ly enrolled patient/subject to continue in the 
study  with or wi thout continued treatment with investigational product.
8.2. Discontinuation from the Study
Patients/
subjects will be discont inued in the fo llowing ci rcumstances:
enrollment in any other clinical trial invo lving an investi gational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study
participat ion in the study needs to be stopped for medical, safet y, regul atory , or other 
reasons consis tent wi th applicable l aws, regul ations, and good clinical pract ice (GCP)
invest igator d ecisio n
othe invest igator decides that the patient/subject shoul d be di scontinued from the 
study
oif the patient, for any  reason, requi res treatm ent with another therapeut ic agent 
that has been demo nstrated to be effect ive for treatment of T2DM , discont inuat ion 
from the study  occurs before introducti on of  the new agent
pati
ent/subject d ecisio n
othe patient/subject or designee, (for exa mple, parents or legal guardian) requests 
to be wi thdrawn from  the study
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 39
LY3298176adverse event
oif a CSE occurs, the invest igational product is to be discont inued and appropriate 
measures taken.  Lilly or its designee should be alerted immediately.  A CSE will 
be defined as a moderate -to-severe A E, abnorm al clinical sign, or clinical 
laboratory  finding that may pose a risk to the well -being of the patient/subject
oa clinically  significant systemic hypersensit ivity reacti on occurs fo llowing 
administration of the investigat ional product (for example, drug-related 
symptom atic bronchospasm, allergy -related edem a/angi oedema, or hy potensio n) 
that requires parenteral medication, does not respond to symptomat ic medicat ion, 
or results in clinical sequelae or an anaphylact ic reaction
at the discretion of the invest igator, if the participant has 2 or more symptomatic 
hypoglycemic episodes (defined as an event with typical hypoglycemic symptoms 
and a measured blood gl ucose ≤63 mg/dL [ 3.5mmol/L] , equivalent to plasma glucose 
≤70 m g/dL [3.9 m mol/L],refer to Secti on9.4.8.3 )
fasting plasma glucose values are >270 mg/dL (approximately  15 m mol/L, equivalent 
to a fast ing blood glucose > 241 m g/dL [13.4 mmo l/L]) on 3 or more separate day s 
over any  2-week peri od between screening and the end of the dosing period
Following the invest igator’s determinat ion that CSE criteria have been met and after the 
investigator’s judgment of relatedness to the inves tigational product is documented, a decisio n 
will be made between the invest igator and Lilly or its designee regarding patient/subject 
discontinuat ion.
The nature of any condit ions, clinical signs or symptoms, or abnormal laboratory  values present 
at the t ime of discont inuat ion and any applicable follow -up procedures will be documented.
Patients/s ubjects who discont inue the study early will have end -of-study  procedures performed 
as shown in the Schedule o f Activities (Section2).
8.3. Patients/Subjects Lost to Follow -up
A patient/subject will be considered lost to follow -up if he or she repeatedly  fails to return for 
scheduled visits and is unable to be contacted by  the study  site.  Si te personnel are expected to 
make diligent attempts to contact patients/subjects who fail to return for a scheduled visit or were 
otherwi se unable to be fo llowed up by the site.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 40
LY32981769.Study Assessments and Procedures
Secti on2lists the Schedule of Act ivities,detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that will be performed for this study .
Appendix 6 provi des a summary  of the m aximum  number and vol ume of invasive samples for all 
sampling during the study .
Unle ss otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applica ble laws, regulat ions, or 
laboratory  certificati on standards.
Invest igators must document their review of each laboratory  safety  report.
9.1. Efficacy Assessments
This sect ion isnot applicable for this study .
9.2. Adverse Events
Invest igators are responsible for monitoring the safety  of patients/subjects who have entered this 
study  and f or alerting Lilly  or its designee to any  event that seem s unusual, even if this event 
may be considered an unant icipated benefit to the patient/subject .
The invest igator is responsible for the appropriate medical care of pat ients/subjects during the 
study .
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or caused the patient/subject to discont inue the investigational product 
before complet ing the study.  The patient/subject shoul d be f ollowed unt il the event resolves, 
stabilizes with appropri ate di agnostic evaluat ion, or i s reasonably  explained.  The frequency  of 
follow-up evaluat ions of the AE is left to the discretion of the investigator.
After the ICF is signed, s tudy site personnel will record ,via eCRF ,the occurrence and nature of 
each patient’s/subject ’s preexist ing condit ions including clinically significant signs and 
symptoms of the disease under treatment in the study .  Addit ionally, site personnel  will record 
any change in the condit ion(s) and the occ urrence and nature of any AEs.
The invest igator will in terpret and docum ent whether or not anAE has a reasonab lepossib ility 
of being related to study treatment or a study  procedure taking into accoun t the disease, 
concomitant treatment ,or pathol ogies.
A “reasonable possibilit y”means that there is a cause -and-effect rel ationship between the 
investigat ional product and/or study  procedure and the AE.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 41
LY3298176Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
If a patient ’s/subject ’sinvestigational product is discontinued as a result of an AE, study site 
personnel must report this to Lilly  or its designee via eCRF .
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inp atient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
event s considered significant by  the invest igator based upon appropriate medical 
judgmen t
When a condit ion related to the dulaglut ide single -use pen necessitates medical or surgical 
intervent ion to preclude either permanent impairment of a body function or permanent damage to 
a body  structure, the serious criteri on of  “requi red intervent ion” will be assigned.
Study  site personnel  must al ert Lilly ,or its designee ,of any SAE wi thin 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.
Although all AEs are recorded in the eCRF after signing informed consent, SAE reporting begins 
after the patient/subject has signed informed consent and has received investi gational product.  
However, if an SAE occurs after signing informed consent, but before receiving invest igational 
product AND is considered reasonably possibly  r elated to a study  procedure then it MUST be 
reported .
Invest igators are not obligated to active ly seek AEs or SAEs in patients/subjects once they  have 
discontinued from and/or com pleted the study  (the patient/subject summary CRF has been 
completed).  However, if the investigator learns of any SAE, including a death, at any  time after 
a patient/ subje ct has been discharged from the study  and he/she considers the event reasonably  
possibly  related to the study  treatm ent or study  parti cipat ion, the invest igator must prompt ly 
notify Lilly.
Pregnancy (maternal or paternal exposure to investigat ional product ) does not meet the definit ion 
of an AE.  However, to fulfill regulatory  requi rements ,any pregnancy should be reported 
following the SAE process to collect data on the outcome for both mother and fetus.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 42
LY32981769.2.1.1. Suspected Unexpected Serious Adverse Reactions
Suspe cted unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
US21 CFR 312.32 and European Unio n Clinical Trial Direct ive 2001/20/EC and the associated 
detailed guidances or nati onal regulatory  requi rements in parti cipat ing countries require the 
reporting of SUSARs .  Lilly has procedures that will be fo llowed f or the recording and expedited 
reporting of SUSARs that are consis tent wi th global regul ations and the associated detailed 
guidances.
9.2.2. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical trials in order to ensure the safet y of study  parti cipants, m onitor quali ty, and facilitate 
process and product improvements.
Patients/s ubjects shoul d be instructed to contact the invest igator as soon as possible if he or she 
has a com plaint or probl em with the invest igational product so that the situation can be asses sed.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of LY3298176 is considered any dose higher than the 
dose assigned through rando mizat ion.  Treatment for overdose is supportive care.
Refer to the IBfor LY3298176 and package insert fordulaglut ide.
9.4. Safety
9.4.1. Laboratory Tests
For each patient/subject , laboratory  tests detailed in Appendix 2 shoul d be conducted according 
to the Schedule of Act ivities (Secti on2).
9.4.2. Physical Examination
Physical examinat ions and routine medical assessments will be conducted as specified in the 
Study  Schedule and as clinically  indicated (Secti on2).
9.4.3. Vital Signs
For each patient/subject , vital signs measurements should be conducted according to the 
Schedule of Act ivities (Secti on2).
Blood pressure and pulse rate should be measured after approximately 5minutes in the supine 
position.
If orthostatic measurements are required, patients/subjects should be supine for approximately
5minutes and stand for at least 3 minutes. If the patient/subject feels unable to stand, supine 
vital signs only  will be recorded.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 43
LY3298176Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms. Addit ional vital signs may be m easured during each study  period if 
warranted and agreed upon between the sponsor and invest igator.
Body  temperature will be measured as specified in the Study  Schedule and as clinically  indicated 
(Secti on2).
9.4.3.1. Body Weight
Weight will be measured as indicated in the Schedul e of Activities (Secti on2). Patients/s ubjects 
will be weighed in light clothing at approximately the same t ime in the morning before dosi ng 
and after an overnight fast and evacuation of bowel and the bladder ,if possible.  During the 
treatm ent peri od, wei ght will be measured twice on each scheduled occasio n, wi th the
pati
ent/subject stepping o ff the scale between measurements. Both weight measurements will be
recorded in the source document and the CRF. Wher ever possible, the same scale will be used
for all  weight m easurem ents throughout the study and the scale will not be m oved or 
recalibrated .
9.4.4. Electrocardiograms
For each patient/subject , ECGs should be co llected according to the Schedule of Act ivities 
(Section2).
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
patient/subject receives the first dose of the invest igational product should be reported to Lilly or 
its designee as an AE via eC RF.
For each patient/subject , asingle ECG will be co llected at screening, Day  
29(Part A only ), and 
follow-up according to the Schedule of Activities(Secti on2).  At all other scheduled times, 
consecut ive replicate ECGs will be obtained in triplicate at approximately 1 -minute intervals.   
ECGs (single) may be obtained at additional t imes when deemed clinically  necessary  (for 
example, to assess patient/ subject safet y).  Collect ion of more ECGs (more replicates) than 
expected at a particular time po int is allowed to ensure high qualit y reco rds.
ECGs must be recorded before collect ing any blood for safet y or PK tests.   Patients/ subjects 
must be supine for approximately 5 to 10 minutes before ECG collect ion and remain supine but 
awake during ECG collect ion.  ECGs may be obtained at addit ional times when deemed 
clinically necessary .  All ECGs recorded should be stored at the invest igational site.
ECGs will be interpreted by  a qualified physician ( the invest igator or qualified designee) at the 
site as soon after the time o f ECG collect ion as poss ible and ideally while the patient/subject is 
still present to determine whether the patient/subject meets entry criteria at the relevant visit(s) 
and for immediate patient/subject management should any  clinically rel evant findings be 
ident ified.
If a clin ically significant quantitative or qualitat ive change fro m baseline is ident ified (including, 
but not limited to, changes in QT/QTc interval from baseline) after enrollment, the invest igator 
will assess the patient/subject for symptom s (for example, palpit ations, near syncope, syncope) 
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 44
LY3298176to determine whether the patient/subject can cont inue in the study .  The invest igator or qualified 
designee is responsible for determining if any  change in patient/subject management i s needed 
and must document his/her review of the ECG printed at the time of evaluation fro m at least 1 of 
the replicate ECGs from each t ime point. Any new clinically  relevant finding shoul d be reported 
as an AE.
Digital ECGs will be electroni cally transmitted to a central ECG laboratory  designat ed by  Lilly .  
The central ECG laboratory  will perf orm a basic quali ty control  check (for example, 
demographics and study  details), then store the ECGs in a database.  At a future time, the stored 
ECG data may be overread at the central ECG laboratory  for further eval uation of  machine -read 
measurements or to meet regulatory  requi rements.
The m achine -read ECG intervals and heart rate may  be used for data analysis and report -writing 
purposes unless a cardio logist overread of the ECGs is conducted before completion of  the final  
study  report (in which case the overread data would be used).
9.4.5. Safety Monitoring
The Lilly clinical pharmaco logist or clinical research physician/scient ist will mo nitor safet y data 
throughout the course of the study .
Lilly will review SAEs within time frames mandated by co mpany procedures.  The Lilly clinical 
pharmaco logist or research physician will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist when appropriate and
periodically  review:
trends in safety data
laboratory  analy tes
serious and nonserious AEs ,including AE s of special interest (GIevents, hypoglycemia, 
inject ion-sitereacti ons, and hypersensit ivity reactions) andreported and adjudicated 
pancreat itis
Further di agnosti c assessments will be recommended whenever lipase and/ or amylase are 
confirmed to be ≥3XULN at any  visit pos ttreatm ent sequence allocat ion even if the 
patient/subject is asymptomat ic (as per the algorithm for the monitoring of pancreat ic events in 
Appendix 5 )and,if pancreat itis is suspected, the case will be further defined during an 
adjudicat ion process. Any patient/subject who develops symptoms of pancreatit is must not 
receive further administration of LY 3298176.
To ensure patient/subject safety and co mpliance with regul atory  guidance, the invest igator is to 
consult with the Lilly designated clinical research physician regarding collect ion of specific 
recommended clinical information and fo llow
-up laboratory  tests .
In the event that safet y monitoring uncovers an issue that needs to be addressed by unblinding at 
the group l evel, addi tional analyses of the safet y data will be conducted by  the personnel 
included in the unblinding/ blinding plan .
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 45
LY32981769.4.6. Immunogenicity Assessments
Blood sam ples f or immunogenicit y testing will  be collected to determine ant ibody  producti on 
against the invest igational product .  Additional samples ma y be collected if there is a possibilit y 
that an AE is immuno logically  mediated.  Imm unogenicit y will be assessed by a validated assay  
designed to detect antidrug antibodies ( ADAs )in the presence of the invest igational product.  
Antibodies may be further characterized and/or evaluated for their abilit y to neutralize the 
activit y of the investigational product .
Samples will  be retained for a m aximum  of 15 y ears after the last patient/subject visit or for a 
shorter period ,if local regulati ons and ERBs allow, at a facilit y selected by  the sponsor.  The 
durati on allows the sponsor to respond to future regulatory  requests related to the invest igational 
product .  Any samples remaining after 15 years will be destroyed.
9.4.7. Hypersen sitivity Reactions
All hypersensit ivity react ions will be reported by  the invest igator as either AEs or, if any serious 
criterion is met, as SAEs.  Dosing should be temporarily discont inued in any individual 
suspected of having a severe or serious allergic /hypersensit ivity react ion to invest igational 
product.  Invest igational product may be restarted if, in the opinio n of the invest igator, the event 
was not related to study  drug and when/if it is safe to do so.  If dosing is permanent ly 
discontinued, the pa tient/subject should remain in the study as needed per medical judgment.
The report of a clinically significant AE of drug reaction or inject ion-site reacti on may prom pt 
notification o f the sponsor, clinical photography , and referral  for derm atologic evaluation and 
consideration of a skin biopsy and la boratory  evaluati ons ( alanine aminotransferase , aspartate 
aminotransferase , com plete bl ood count wi th percent eosin ophils, and addit ional 
immunogenicit y testing).
9.4.7.1. Injection- Site Reactions
If an injection -site reacti onis present, it will be fully characterized (including erythema, 
induration, pain, itching , and swelling ) and will be cl osely  monitored until  resol ution.
Invest igational site staff will be provided with separate instructions/training onhow to
consistent ly evaluate injection -site reacti onsand thei r severi ty. Photographs of inject ion-site 
reacti onsmay be taken in a standardized fashio n for record -keeping purposes; however, the 
photographs will not be used to evaluate injection -site reacti onseverit y.
9.4.8. Glucose Monitoring
9.4.8.1. Part A
Blood gl ucose will be mo nitored for safet y according the Schedule of Act ivities (Secti on2).
9.4.8.2. Parts B and C
Patients/subjects will be instructed on how to use the glucose meter provided by the site and 
conduct self -blood glucose monitoring tests .In addit ion to the glucose monito ring and fast ing 
glucose m easurements , patients/subjects will be educated on the symptoms of hypoglycemia.  
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 46
LY3298176Throughout their parti cipati on in the study , pati ents/s ubjects will mo nitor blood gl ucose levels.  
Patients/s ubjects will be provided a diary  card and instructed to record blood glucose results 
prem eal and bedt ime on at least 3 days per week during the dosing phase of the study  and 
whenever the patient/ subject experiences symptoms of hypoglycemia .  Invest igator review o f 
glucose resul ts clinically indicat ive of hypoglycemia or hy perglycemia is required.
Addit ionally , patients with T2DM (Part C) who were taking sulfo nylureas at screening will be 
requi red to m onitor thei r glucose during the 6 -week washout period.
9.4.8.3. Hyperglyc emia and Hypoglycemia Reporting
Episodes of hyperglycemia (fasting plasma glucose >270 mg/dL [15 mmo l/L],equivalent to a 
fasting blood glucose > 241 m g/dL [13.4 mmo l/L]) or hy poglycemia (blood glucose ≤63 m g/dL
[3.5 mmo l/L], equivalent to plasma glucose 70 mg/dL [3.9 mmo l/L]) will be reported by  the 
investigator or designated physician who will be responsible for advising the patient/subject on 
what further actions to take. Addit ional mo nitoring may  be requested at the invest igator’s 
discreti on.
If the fas ting glucose during the dosing period exceeds the acceptable level defined as 
hyperglycemia on 3 or more separate days over any 2 -week peri od between screening and the 
end of the dosing period, the patient/subject will be evaluated further at the study  site.  If  fasting 
glucose continues to exceed the acceptable level, study  drug will be discont inued and treatment 
with an appropri ate anti diabet icagent m ay be initiated by  the i nvest igator for pati ents wi th 
T2DM .  The patient will cont inue to be fo llowed in the study  (for saf ety, PK, and 
immunogenicit y assessment) for at l east 28 day s after his/her last dose.  If hyperglycemia occurs 
during the fo llow-up peri od, the pati ent will remain in the study  until completion o f the planned 
follow-up.
Hypoglycemia episodes will be recorded on specific CRF pages.  Hy poglycemia will be treated 
appropriately  by the investi gator and addi tional moni toring of blood glucose levels may  be 
perform ed. The following definit ions of the Ame rican Diabetes Associat ion (ADA) and 
Endocrine Societ y Workgroup on Hy poglycemia and Diabetes (Seaqui st et al . 
2013) shoul d be 
applied for reporting in the CRF and evaluat ing hypoglycemic events:
Severe Hypoglycemia:   An event during which the patient req uires the assistance of 
another person to actively administer carbohydrate, glucagon, or other resuscitative 
actions.  These epi sodes may  be associ ated wi th sufficient neuroglycopenia to induce 
seizure or coma.  Plasma glucose measurements may  not be avail able during such an 
event, but neurological recovery attributable to the restoration of plasma glucose to 
norm al is consi dered sufficient evidence that the event was induced by  a low pl asma 
glucose concentration.
Documented Symptomatic Hypoglycemia:   An ev ent during which ty pical symptom s 
of hypoglycemia are acco mpanied by a measured blood glucose concentration 
≤63mg/dL (3. 5mmo l/L), equivalent to plasma glucose 70 mg/dL (3.9 mmo l/L).
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 47
LY3298176Asymptomatic Hypoglycemia:   An event not accompanied by t ypical symptoms of 
hypoglycemia but with a measured blood glucose concentration ≤63mg/dL 
(3.5mmo l/L), equivalent to plasma glucose 70 mg/dL (3.9 mmo l/L).
Probable Symptomatic Hypoglycemia:   An event during which symptoms of 
hypoglycemia are not accompanied by a blood g lucose m easurement but that was 
presum ably caused by a blood glucose concentration ≤63mg/dL (3. 5mmo l/L), 
equivalent to plasma glucose 70 mg/dL (3.9 mmo l/L).
Relative Hypoglycemia:   An event during which the pat ient reports any  of the ty pical  
symptoms of hypoglycemia and interprets those as indicative of hypoglycemia but with a 
measured blood glucose concentrati on >63 mg/dL (3. 5mmo l/L), equivalent to plasma 
glucose 70 mg/dL (3.9 mmol/L).
If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious in the
CRF (that is, recorded as an SAE).   In the case of a hypoglycemic event (other than severe), the 
actual glucose value, if measured, should be recorded in the CRF, together with any treatments 
administered and not be recorded as an AE.  Cases of hypoglycemia may be treated with foods 
rich in carbohydrate such as fruit, juice, skimmed milk, or energy  bars.  All episodes of 
hypoglycemia that are determined by the investigator to constitute severe hypoglycemia 
according to the definit ion above should be reported as SAEs.
9.4.9. Nausea andVomiting
Nausea andvomiting events are considered AEs of interest and will be recorded as AEs in the
CRF.  For each event assessme nt of severit y, durati on and investi gator’s opini on of  relatedness 
to study  drug and protocol procedure will be captured.
9.4.10. Elevated Lipase or Amylase
Serum  amylase and lipase measurements will be collected as part of the clinical laboratory  
testing at time points specified in the Schedule of Act ivities (Secti on2).  Addi tional 
measurements may  be perform ed at the invest igator’s discretion.  Further diagnostic assessments 
will be reco mmended as per the algorithm (refer to Appendix 5 ) for the m onitoring of pancreat ic 
events whenever lipase and/or amylase is confirmed to be ≥3X ULN at any visit 
postrandomizat ion, even if the pat ient/subject is asymptomat ic.
9.5. Pharmacokinetic s
At the visit s and t imes specified in t he Schedule of Act ivities
(Secti on2), venous blood samples 
of approximately  5mL each will be co llected to determine the plasma concentrati ons of  
LY3298176 .  A maximum o f 3samples m ay be collected at addit ional time points during the 
study  if warranted and agreed upon between both the invest igator and sponsor.
Instructi ons for the collect ion and handling of blood samples will be provided by the spo nsor.  
The actual  date and time (24-hour clock time) of each sampling will be recorded.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 48
LY3298176Drug concentration informat ion that m ay unblind the study  will not be reported to invest igative 
sites or blinded personnel unt il the study has been unblinded.
9.5.1. Bioanalys is
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor.
Concentrations of LY3298176 will be assayed using validated liquid chromatography mass 
spectrometry  (LC/MS) method.  Analyses of samples collected from placebo -treated 
patients/subjects are not planned.
Bioanaly tical samples collected to m easure invest igational product concentrations will be 
retained for a maximum o f 1 year following l ast patient/subject visit for the study .
9.6. Pharmacodynami cs
Preliminary assessment of LY3298176 pharmacology  in healt hy subjects in Part B will be 
evaluated based on glucose and insulin fro m the OGTT and acetaminophen for gastric empt ying.  
LY3298176 PD assessment in pat ients with T2DM (Part C) may include fast ing glucose, insulin, 
total cholesterol , high -densit y lipoprotei n and low-densit y lipoprotein cholesterol, triglycerides, 
body  weight, area under the concentration versus t ime curves ( AUCs )for glucose, insulin 
associ ated wi th the OGTT , and acetaminophen for gastric empt ying.   Addit ional exploratory  PD 
analysis may  be analyzed as deemed appropriate.
Blood sam ples will be obtained for the measurement of PD. The scheduled times for the 
collect ion of these samples are as listed in the Schedul e of Activities (Secti on2).The timing of 
PD sam ples is intended to assess pharm acologic effects of LY3298176.  The sampling times may 
be modified at the di scret ion of the sponsor, but the total  number of the samples or total blood 
volume will not increase.
The sample(s) will be stored for up to a maximum  of1year after the l astpatient/subject visit for 
the study  at a f acilit y selected by  the sponsor.
9.6.1. Glucose Samples
Serum  concentrati ons of  glucose from  the clinical laboratory  samples and g lucose only samples, 
as indicated in the Schedule of Act ivities (Section 2),will be assayed using validated analyt ical 
methods.  Instructions for the collect ion and handling of blood samples for these analyses will be 
provi ded by the sponsor.
9.6.1.1. Oral Glucose Tolerance Test (Parts B and C)
Glucose and insulin will be measured in an OGTT to assess effects of LY3298176 on glycemic 
control , disposi tion index, and insulin sensit ivity.  The schedule for OGTTs is indicated in the 
Schedule of Act ivities (Section 2).
Patients/subjects shall maintain adequate carbohy drate intake 3 day s before the scheduled 
OGTT.  Pati ents/subjects shall fast for approximately 8 hours overnight before administration of 
the OGTT.  A 75
-gram glucose dose will be given orally .  Pati ents shoul d consume the glucose 
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 49
LY3298176load wi thin 5 minutes.  If patients develop symptoms of hypoglycemia, bedside blood glucose 
concentration may  be measured and the patient will be treated per investi gator discret ion.  Blood 
samples will be drawn for assessment of glucose and insulin pretest and at 0.5, 1, 1.5, and 
2hours after the init iation of the glucose load.
9.6.1.2. 7-Point Glucose Monitoring (Parts B and C)
Patients/subjects will be asked to perform a 7- point blood glucose profile according to the 
Schedule of Act ivities (Section 2).  Pati ents will  be asked to test their self -monitored bl ood 
glucose levels before each meal, approximately 2 hours after each meal, and at bedtime.  
Patients/subjects will be asked to record their self -monitored bl ood gl ucose levels in their diaries 
according to instructions.  The complete 7 -point blood glucose profile m ust be com pleted on a 
single day.  If a patient does not complete the entire profile on a single day, all 7 po ints must be 
collected on a subsequent day except for the predose baseline onDay -2 that will need to be 
completed on that same dayto avoi d inte rference wi th the OGTT that will be administered on the 
subsequent day .
9.6.2. Gast ric Emptying (Parts B and C)
Acetaminophen is a well -established marker for the rate and extent of gastric empt ying (Young 
2005). It is rapidly absorbed from the duodenum upon release fro m the stom ach.  A delay in 
gastri c empt ying is reflected in the alterati ons to the concentration -time profile of 
acetaminophen, specifically, decreasing its Cmaxand Tmaxwithout al tering the extent (total drug 
amount) absorbed. A dose of appro ximately 1g acetaminophen is considered to be sufficient for 
bioanalyt ical detection and will be administered on Day  -1 and about 24 h ours after first and 
fourth LY 3298176 dosesin Part B and Part C (refer to Schedule of Activit ies[Secti on2]).  The 
acetaminophen dose should be given soon after the 75-g glucose dose for the OGTT.
Venous blood samples of approximately 2 mL each will be co llected to determine the plasma 
concentrations of acetaminophen.
9.6.2.1. Bioanalysis
Concentrations of acetaminophen will be assayed using validated LC/MS method.  Analyses of 
samples co llected fro m placebo -treated pati ents/subjects are not planned.
9.6.3. Bone Biomarkers
To invest igate the effects of LY3298176 on bone metabo lism (absorption and resorption) 
following mult iple doses in T2DM (Part C), the fo llowing bio markers will be assessed:  serum  
carboxy -terminal tel opepti de fragments of Ty pe I collagen (CT X
-1), N -terminal propept ide o f 
Type I collagen (P1NP), and osteocalcin.
9.7. Genetics
A blood sample will be collected for pharmacogenetic analysis as specified in the Schedule of 
Activities(Secti on2), where local regulat ions allo w.
Samples willnotbeused to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate varia ble response to LY3298176 and to 
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 50
LY3298176investigate genet ic variants though t to pl ay a rol e inT2DM and related complicat ions.  
Assessment of variable response may  include evaluati on of  AEs or differences in efficacy.
All samples will be coded with the patient/su bject number.  These samples and any data 
generated can be linked back to the patient/subject only by the invest igativesite personnel .
Samples will  be retained for a m aximum  of 15 y ears after the last patient/subject visit or for a 
shorter period if local regulat ionsand/or ERBs impose shorter time limit sfor the study  at a 
facilit y selected by Lilly .  This retention period enables use of new technologies, response to 
regul atory  questi ons, and invest igation of variable response that may not be observ ed unt il later 
in the devel opment of LY3298176 or after LY3298176 is commercially available.
Molecular techno logies are expected to improve during the 15 -year storage period and ,therefore ,
cannot be specifically  named.  However, e xisting approaches include whol e genom e or exome 
sequencing, geno me-wide associ ation studies, multiplex assays, and candidate gene studies .  
Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion.
9.8. Biomarker s
Biomarker research is performed to address questions of relevance to drug di sposi tion, target 
engagement, PD, mechanism of act ion, variabilit y of patient response (including safety ), and 
clinical outcome.  Sample co llection is incorporated into clinical studies to enable examinat ion of 
these quest ions through measurement of bio molecul es including deoxy ribonuclei c acid ( DNA ), 
ribonucleic acid ( RNA ), proteins, lipids, and other cellular elements.
Serum andplasma samples for non pharmaco genetic bio marker research will be co llected at the 
times specified in the Schedule of Act ivities (Section 2) where local regulat ions allow.
Samples will be used for research on the drug target ,disease process, variable response to 
LY3298176 , 
pathway s associ ated wi th T2DM , mechanism  of action of  LY3298176 , and/or 
research method, or for validat ing diagnost ic tools or assay (s) related to T2DM .
All samples will be coded with the patient/subject number.  These samples and any data 
generated can be linked back to the patient/subject only by the invest igativesite personnel .
Samples will  be retained for a m aximum  of 15 y ears after the last patient/subject visit or for a 
shorter period if local regulat ionsand/or ERBs impose shorter time limit s,at a facilit y selected 
byLilly .  This retenti on peri od enables use of new techno logies, response to regulatory  
questions, and invest igation of variable response that may not be observed unt il later in the
development of LY3298176 or after LY3298176 is commerci ally available.
9.9. Health Economics
Thissection is not applicable for this study.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 51
LY329817610. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Approximately 143 healt hy subjects m ay be enrolled in Part sA and Part Bto achieve the 
objectives of each part of the study .Approximately 25T2DM pat ients may be enro lled in Part C 
to achieve study objectives.   The replacement patient/subject will be assigned to receive the 
treatm ent of the dropout.
For each study  part, any dropout m ay be repl aced so that the targeted numbers of 
patients/subjects for safet y review and data collect ion may be achieved.  The replacement 
patient/subject will be assigned to receive the treatment of the dropout.
The sample sizes for each part of the study  were chosen to provide adequate placebo control for 
each dosing occasio n and are considered sufficient to evaluate the primary object ive o f this 
study .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
All patients/subjects who di scont inue from the study  will be i dentified and the extent of their 
participat ion in the study will be reported. If known, a reason for their discont inuat ion will be 
given.
10.2.2. Study Participant Characteristics
The patient’s/subject’s age, sex, weight, height, or other demographic characterist ics will be 
recorded and may be used in the PK, PD, and safety analyses as quantitative or classificat ion 
variables.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee.
PK and PD analyses will be conducted on the full analysis set. This set includes all data from all 
enrolled patients/subjects receiving at least 1 dose of the study  drug according to the treatment 
the patients/subjects actually received. Safet yanalyses will be conducted for all enrolled 
patients/subjects whether or not they  com pleted all protocol requirements.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate. Statist ical 
analyses will be fully detailed in the statistical analysis plan.
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All invest igational product –and protocol procedure –related AEs will be listed, and if the 
frequency  of events all ows, safet y data will be summari zed using descriptive methodology .
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 52
LY3298176The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with invest igational product as perceived by the investigator. Symptoms reported to occur 
before the first study  drug dosing will be dist inguished fro m those rep orted as new or increased 
in severit y during the study . Each symptom will be classified by the most suitable term fro m the 
medical regulatory  dictionary.
10.3.1.2. Statistical Evaluation of Safety
Safety param eters that will be assessed include safety  laboratory parameters, vi tal signs, and 
ECG parameters.
Laboratory  measurements will be summari zed wi th respect to observed values and change fro m 
baseline by treatment group at each time point using descript ive statist ics.In addit ion, all 
clinical chemistry , hematol ogy, and urinalysis data outside the reference ranges will be tabulated 
by parameter and treatment group.
Vital signs will  be summari zed wi th respect to observed values and change from baseline (Day 1,
predose) by treatment at each time point using descript ive statist ics.For change fro m baseline 
values, a mixed -model repeated -measure (MMRM) m odel with treatm ent, time (of 
measurement) , and treatment -
by-timeinteracti on as fixed effects, patient/subject as random
effect, and baseline as covariate will be used to determine the effects of LY3298176. The m ean 
of triplicate m easurements at each time point will be used for summary  and analysis.
ECG parameters ,includ ingthe PR, QT, RR ,and QT c using Fridericia’s form ula (QTcF) 
intervals, QRS durati on, and heart rate , will be summariz ed.  The number and percentage of 
patients/subjects wi th a maximum  increase from  baseline in QTcF interval will be summari zed 
for each treatm ent group according to the fo llowing categori es:>30 m sec and >60 msec. In 
addition, the number and percentage of patients/subjects with QTcF postdose values according to 
the following categori es:>450 m sec, >480 m sec, and >500 msec, will be summarized by 
treatm ent group. Analyses m ay be performed t o determine the effects of PK and PD parameters 
on QTcF.
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
PK parameter estimates for LY3298176 will be calculated by  standard noncom partmental 
methods of analysis.   The primary parameters for analysis will be C max, AUC , and Tmaxof 
LY3298176 .  Other parameters, such as half -life, apparent clearance, and apparent volume of 
distribut ion,may be reported.   If deem necessary , addi tional model-based analysis may be 
perform ed.
10.3.2.2. Pharmacokinetic Statist ical Inference
For single -and m ultiple-dose parts of the study , PK dose proporti onali ty will be assessed 
separately . Log-transform ed C maxandAUC of LY3298176 will be evaluated using a power 
model (where log-dose acts as an explanatory  variable) to estim ate rati os of dose -normalized 
geom etric means and corresponding 90% confidence intervals (CIs) . The estimated ratio of 
dose-norm alized geometric m eans of PK parameters between the highest and lowest doses will 
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 53
LY3298176be used to assess dose proportionalit y. A subinterval within the highest and lowest doses may  
also be considered for assessment of dose proportionalit y using the sam e approach.
The parameter Tmaxof LY3298176 will be analyzed using a nonparametric method.
For Parts A, B, and C, all PK parameters wil l be summarized using descriptive statist ics.
10.3.3. Pharmacodynamic Analyses
Inferences will be sought regarding the abilit y of LY3298176 to reduce fast ing or dynamic 
glucose together with the effects on insulin. Such effects will be explored over different doses of 
LY3298176.
10.3.3.1. Pharmacodynamic Parameter Estimation
TheAUC for gl ucose and insulin during an OGTT will be calculated using the trapezoidal rule. 
The AUC as well as derived parameters or observed concentration at specific time po ints for 
each patient/subject on the study  day will also be baseline -adjusted. The concentrations on 
Day −1will be used as baseline.
Theparam eter estimates for acetaminophen will be calculated by  standard noncom partmental 
methods of analysis. The primary parameters for ana lysis will be the Cmax, the AUC , and the 
Tmaxof acetaminophen.  Other parameters, such as half -life, apparent clearance, and apparent 
volume of distribut ion, may be reported.
10.3.3.2. Pharmacodynamic Statistical Inference
The PD param eters fro m each part of the st udy will be analyz ed separately . PD param eters fro m 
placebo -treated patients/ subjects wi thin each part of the study  will be pooled for the final 
analysis. PD parameters may be transformed beforestatistical analyses ,if deemed necessary. 
Absolute values as well as change from baseline in each parameter will be analyzed using 
mixed -effects m odels to eval uate treatment effects as well as treatment comparisons. The model 
will include treatment, day , and treatm ent-by-day interacti on as fixed effects and patient/subject 
as a rando m effect. Baseline (Day −1) values, as well as other influencing variables, may  be 
used as covariates. The m ain co mpar isons will be between each LY 3298176- treated group and 
placebo group.
Baseline -adjusted C maxof acetaminophen (ratio to Day  
-1 value) will be calculated and 
log-transform ed to com pare the gastri c empt ying effect of LY3298176 to that of dulaglut ide.  A n
MMRM with treatment, day , and treatm ent-
by-day interacti on as fixed effects, patient/subject as
rando m effect, and baseline (Day  -1) as covari ate will  be used to perform the analysis.  
Least -squares means as well as 95% CIs will be reported.
The parameter Tmaxof acetaminophen will be analyzed using a nonparametric method .
All PD parameters, includi ng the baseline -corrected parameters, will be summarized and 
tabul ated by  treatm ent group and day . Summary  stati stics will be provided.
The individual observed and mean t ime profile o f the postdose PD parameters will be plotted by  
treatm ent group.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 54
LY329817610.3.4. Pharmac okinetic/Pharmacodynamic Analyses
PK/PD m odeling may  be evaluated to characterize the exposure -response relat ionships between 
LY3298176 concentrations and various PD endpo ints, provi ded data are sufficient.
10.3.5. Evaluation of Immunogenicity
The frequency of ant ibody  formati on to LY3298176 will be determined.  If a neutralizat ion assay  
is performed, the frequency o f neutralizing antibodies will be determined.  The relat ionship 
between the presence (or absence) of ant ibodies and clinical parameters ( for example, AEs, 
efficacy  measures) will be assessed.  Likewise, the relat ionship between the presence o f 
antibodies and the PK parameters and PD response to LY3298176 will be assessed.
10.3.6. Interim Analyses
The Lilly sponsor team is unblinded.  Data may be analy zed while the trial is ongoing.  An 
assessment committee will not be formed.
Access to the data i s scheduled to occur after every dosing sessio n.  The purpose of these reviews 
is to review the safet y data for the next dosing sessio n.  The invest igator and the Lilly sponsor 
team  will make the determinat ion regarding dose escalat ion based upon their review of the safet y 
and tol erabilit y data.  The invest igator will remain blinded ,and the Lilly sponsor team  will be 
unblinded during these reviews.
The first interim anal ysis supporting init iation of the MAD porti on of  the study (Part B )will be 
based on review of safet y and PK data from Day 8 of the second SAD dose level and safet y data 
through Day  8 of the thi rd SAD dose level .Thesedata may be used to update PK sampli ng 
timesand dose sel ection for the rem aining cohorts.  The second interim analysis supporting 
initiation of Part C will be based on available data fro m Part B (MAD).
The third interim  analysis will include data through Day  29of the highest MAD dose l evel 
(Part B) and Day 2 9of the T2DM cohort (Part C), excluding ADA assessment.  The datawill 
include but are not limit ed to available safet y, PK ofLY3298176 and acetaminophen (Parts B 
and C only) , and OGTT (Parts B and C only) .
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 55
LY329817611. References
Amori RE, Lau J, Pittas AG. Efficacy  and safet y of incret in therapy in t ype 2 diabetes: 
system atic review and meta -analysis. JAMA . 2007;298(2):194 -206.
Baynes KCR. The evo lving world of GLP -1 agonist therapies for ty pe 2 di abetes. Ther Adv 
Endo crinol Metab . 2010;1(2):61 -67.
Drucker DJ, Nauck MA. The incretin system: glucagon -like peptide -1 receptor agoni sts and 
dipeptidyl pept idase -4 inhibitors in t ype 2 diabetes. Lancet . 2006;368(9548):1696- 1705.
[EMEA] European Medicines Agency .Guideline on s trategi es to i dentify and mit igate ri sks for 
first-in human clinical trials wit h investigational medi cinal products.
EMEA/CHMP/SWP/28367/07. 2007.
Finan B, Ma T, Ottaway N, Müller TD, Habegger KM,Heppner KM,Kirchner H, Holland J, 
Hembree J, Raver C,Lockie SH,Smiley DL, Gelfanov V, Yang B, Hofmann S,Bruemmer D,
Drucker DJ, Pfluger PT, Perez -Tilve D,Gidda J, Vignat i L, Zhang L, Hauptm anJB, Lau M, 
Brecheisen M,Uhles S, Riboulet W, Hainaut E, Sebokova E,Conde -Knape K, Konkar A, 
DiMarchi RD,Tschöp MH. Unimo lecular dual  incretins maximize metabo licbenefi ts in 
rodents, monkeys, and humans. SciTrans lMed.2013 ;5(209):209ra151.
Goodwill AG, Mather KJ, Conteh AM, Sassoon DJ , Noblet JN, Tune JD. Cardiovascular and 
hemodynamic effects of glucagon- like pept ide-1. Rev Endocr Metab Disord . 
2014;15 (3):209-217.
Irwin N, Hunter K, Frizzell N, Flatt PR. Ant idiabetic effects of sub- chroni c act ivation of the GIP 
receptor alone and in combinat ion with background exendin -4 therapy  in high fat fed mice. 
Regul Pept . 2009;153(1- 3):70 -76.
Kim SJ, Ni an C, Karunakaran S, Clee SM, Isales CM, McIntosh CH .GIP-overexpressing mice 
demonstrate reduced diet -induced obesit y and steatosis, and improved glucose ho meostasis. 
PLoS One 7 .2012;7(7): e40156.
Nauck MA, Baller B, Meier JJ. Gastric inhibitory  polypept ide and glucagon -like pept ide-1 in the 
pathogenesis of type 2 di abetes. Diabetes . 2004;53( suppl 3):S190 -S196.
Seaquist ER, Anderson J, Childs B, Cry er P, Dagogo -Jack S, Fish L, Heller SR, Rodriguez H, 
Rosenzweig J, Vigersky  R. Hypoglycemia and diabetes: a report of a workgroup of the 
American Diabetes Associa tion and the Endocrine Societ y. Diabetes Care . 
2013;36(5):1384 -1395.
Trulicit y [package insert]. Indi anapo lis, IN: Eli Lilly and Company; 2015.
Young A. Inhibit ion of gastri c em ptying. Adv Pharmaco l. 2005; 52:99 -121.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 56
LY3298176Appendix 1. Abbreviations and Definitions
Term Definition
ADA antidrug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
AUC area under the concentration versus tim e curve
blinding A procedure in which one or more parties to the trial are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient/subject is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient/subject are no t.  A double -blind 
study is one in which neither the patient/subject nor any  of the investigator or sponsor staff 
who are involved in the treatment or clinical evaluation of the subjects are aware of the 
treatment received
BP British Pharmacopeia or blood pressure
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
Cmax maximum drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the trial -related requirements, good clinical practice (GCP) requirements, 
and the applicable regul atory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur imme diately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CRF case report form
CRU clinical research unit
CSE clinically significant event
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 57
LY3298176CTX-1 carboxy -terminal telopeptide fragments of Type I collagen
DPP dipeptidy l peptidase
ECG electrocardiogram
eGFR estimated glomerular filtration rate
enroll The act of assigning a patient/subject to a treatment.  Patients/ subjects who are enrolled in 
the trial are those who have been assigned to a treatment.
enter Patients/ subjects entered into a trial are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERB ethical review board
GCP good clinical practice
GI gastrointestinal
GIP glucose -dependent insulinotropic polypeptide
GLP-1 glucagon -like peptide -1
HbA1c hemoglobin A1c
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Conference on Harmoni sation
informed consent A process by which a patient/subject voluntarily confirms his or her willingness to 
participate in a particular trial, after having been informed of all aspects of the trial that are 
relevant to the patient ’s/subject ’sdecision to participate.  Informed consent is documented 
by means of a wr itten, signed and date d informed consent form.
interim analysis An interim analysis is an analysis of clinical trial data, separated into treatment groups, that 
is conducted before the final reporting database is created/locked.
Investigational 
product ( IP)A pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical trial, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or m arketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator A person responsible for the conduct of the clinical trial at a trial site.  If a trial is conducted 
by a team of individuals at a trial site, the investigator is the responsible leader of the team 
and may be called the principal investigator.
IWRS interactive web response system
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 58
LY3298176Ki inhibito ry constant
LC/MS liquid chromatography mass spectrometry
Legal 
RepresentativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective patient/subject , to the patient/subject ’sparticipation in the clinical 
trial.
MAD multiple -ascending dose
MMRM mixed- model repeated-measure
MTD maximum -tolerated dose
NOAEL no-observed -adverse -effect level
Non-
investigational 
product (non -IP)A product that is not being tested or used as a reference in the clinical trial, but is provided 
to subjects and used in accordance w ith the protocol, such as:  concomitant or rescue/escape 
medication for preventative, diagnostic, or therapeutic reasons, medication to ensure 
adequate medical care, and/or products used to induce a physiological response.
open -label A study  in which ther e are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
OGTT oral glucose tolerance test
P1NP N-terminal propeptide of Type I collagen
PD pharmacodynamic (s)
PK pharmacokinetic(s)
QTc QT corrected for heart rate
QTcF QTc using Fridericia’s formula
SAD single -
ascending dose
SAE serious adverse event
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical trial.
SRP Safety Review Panel
SUSARs suspected unexpected serious adverse reactions
T2DM type 2 diabetes mellitus
Tmax time to C max
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 59
LY3298176ULN upper limit of normal
US UnitedStates
USP US Pharmacopeia
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 60
LY3298176Appendix 2. Clinical Laboratory  Tests
Laboratory Tests
Hematology Clinical Chemistry (fasting)
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Serum c reatinine
Mean cell hemoglobin concentration Calcium
Leukocytes (WBC) Phospho rus
Absolute counts of: Glucose, fasting
Neutrophils Blood urea nitrogen
Lymphocy tes Uric acid
Monocytes Total protein
Eosinophils Albumin
Basophils Total bilirubin
Platelets Alkaline phosphatase
Alanine aminotransferase
Urinalysis Aspartate aminotransferase
Specific gravity Lipase, fasting
pH Amylase
Protein Triglyceride b
Glucose Total cholesterol b
Ketones
Bilirubin Serology c
Urobilinogen Follicle -stimulating hormone a
Blood Hepatitis B surface antigen
Leukocytes Hepatitis C antibody d
Microscopy a HIV antibody
Pregnancy test (urine, serum) e
Drug and alcohol screen f
Abbreviations:  HIV = human immunodeficiency virus; RBC = red blood cells, WBC = white blood cells.
Note:  Results of these assays will be validated by the central or local laboratory at the time of testing.  Additional 
tests may be performed or auto -calculated by the laboratory as part of its standard panel that cannot be removed.  
Some of the above parameters are calculated from measured values.  Omission of calculated values will not be 
considered as a protocol violation.
aIf clinically indicated, per investigator’s discretion.
bTriglyceride and total cholesterol concentrations in the safety panel will not be required on the days that the lipid 
panel is performed.
cAt screening only (unless previously performed within the last 6 months with reports available for review).
dUnitedStates only.
ePregnancy tests (females, as appropriate) will be performed at the investigator’s discretion.
fPerformed at a local laboratory only at site(s) located in the United States.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 61
LY3298176Appendix 3. Study  Governance, Regulatory ,and 
Ethical Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the patient/subject understands the potential risks and benefits of 
participat ing in the study .
ensuring that informed consent is given by each patient/subject or legal representative.  
This includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of invest igational 
product.
answering any quest ions the patient/subject may have throughout the study  and sharing 
in a timely  manner any  new inform ation that m ay be relevant to the patient ’s/subject ’s
willingness to continue his or her participat ion in the trial.
Ethical Review
The invest igator must give assurance that the ERB was properly const ituted and con vened as 
requi red by ICH gui delines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s). All ICFs must b e com pliant wi th the ICH gui deline 
on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
Regulatory Considerations
This study  will be conducted in accor dance wit h:
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council forInternational
Organizat ionsofMedical Sciences (CIOMS ) international ethical guid elines
2)applicable ICH GCP Guidelines 
3)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party  organi zation.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 62
LY3298176Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly r epresentative.
Final Report Signature
The final report coordinat ing invest igator or designee will sign the clini cal study  report for this 
study indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and resul ts of the study .
The invest igator with the most enrolled pat ients/subjects will serve as the final report 
coordinat ing investigator.  If this invest igator is unable to fulfill this funct ion, another 
investigator will be chosen by  Lilly to serve as the final report coordinat ing investigator.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clini cal 
study  report for this study confirming that, to the best of his or her knowledge, the report 
accurately describes the c onduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
provi de training to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion ofthe CRFs, and study  procedures
make pe riodic visi ts to the study  site
be available for consultation and stay  in contact with the study  site person nelby mail, 
telephone, and/or fax
review and evaluate CRF data and/or use standard computer edits to det ect errors in data 
collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives will periodically check a sample of the patient/subject
data recorded against source documents at the study site.  The study  may be audi ted by Lilly 
and/or regulatory  agencies at any  time.  Investigators will be gi ven noti ce before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original source 
docum ents.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 63
LY3298176Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The si te must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
Any data for which paper documentation provided by the patient /subject will serve as the source
docum ent will be i dentified and documented by  each si te in that si te’s study  file. Paper
docum entati on provi ded by  the pat ient/subject may include, for example, a paper diary  to collect 
patient/subject -reported outcome measures (for example, self -monitored gl ucose values), a daily 
dosing schedule, or an event diary.
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions,and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 64
LY3298176Appendix 4. Clinically  Significant A dverse Effects
The table bel ow summarizes the ty pe and severit y of symptoms, clinical signs, and clinical 
laboratory  findings that m ay qualify  as a CSE.  These are intended as a guideline to the 
investigator(s), not as a set of abso lute criteria.  The underlying principle is to defin e a level of 
moderate -to-severe abnormalit y in safet y findings that could cause harm to health and would 
precl ude further dosing o f a pati ent/subject who experiences this effect.  Safet y parameters not 
included in this table may be interpreted in a similar fashion according to invest igator judgment.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 65
LY3298176Clinically Significant Adverse Effects
Parameter CSE level
Symptoms
Severe hy poglycemia One episode of severe hypoglycemia defined as low blood glucose with mental 
status impairment severe enough to require third party assistance.
Dizziness/hypotension Orthostatic CNS symptoms (dizziness, confusion) that are not vasovagal responses 
to provocative stimuli (for example, phlebotomy, nausea, bowel or bladder 
function), and are associated with orthostatic SBP decrease >20 mm Hg or DBP 
decrease >10 mm Hg or he art rate >105 bpm, for >3 hours 
Sensorium Disorientation to time, place, or identity.  Any abnormal ideation
Mood Feelings of grief or loss that interfere with study procedures or activities of daily 
living.  Any suicidal ideation.
Headache/pain Any focal or generalized head pain that disrupts normal activities and is not 
responsive to medical therapies
Pruritus Generalized itching over >24 hours unresponsive to oral antihistamine
Signs
Systolic blood pressure >30 mm Hg increase from baseline valu es and an absolute level >190 mm Hg
Diastolic blood pressure >20 mm Hg increase from baseline values and an absolute level >115 mm Hg
Heart rate Resting (sitting or recumbent) HR >120 bpm
Cardiac Rhythm Any rhythm other than sinus rhythm, mild sinus bradycardia ,or mild sinus 
tachycardia
QTc >500 msec or >60 msec increase from baseline value
QRS morphology Significant prolongation of QRS interval or new onset of bundle branch block
Tremor Readily  visible tremor during normal movement deemed unrelat ed to hypoglycemia
Reflexes New onset of clonic reflexes
Clinical Laboratory (confirmed by repeat measurements within 48 hours)
Hemoglobin Absolute value <10 g/dL and >2 g/dL reduction from baseline
Neutropenia Absolute neutrophils <1,500/μL and > 1,000 L decrease from baseline
Lymphopenia Absolute lymphocyte count <800/μL and >500/ L decrease from baseline
Platelet count <75,000/μL and >50,000/ L decrease from baseline
Creatinine >2 mg/dL and >0.5 mg/dL increase from baseline value
Urea >8 mmol/L and >3 mmol/L increase from baseline values
Alanine aminotransferase >5-fold above laboratory reference upper limit value
Aspartate 
aminotransferase>5-fold above laboratory reference upper limit value
Bilirubin (total) >1.5-fold above laboratory reference upper limit value
Potassium <2.5 or >5.5 meq/L and >0.5 meq/L change from baseline value
Sodium <130 or >150 meq/L and >10meq/L change from baseline value
Abbreviations:  CNS = central nervous system, CSE = clinically significant effect, DBP = diastolic blood pressure, 
HR = heart rate, SBP = systolic blood pressure.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 66
LY3298176Appendix 5. Pancreatic Monitorin g
GLP -1 agoni sts have been associated with a possible risk of acute pancreatit is.  In 2006, the US 
prescribing information for exenat ide was revised to include the event of pancreat itis.  In 2007, 
the US prescribing information for this medicat ion was am ended to include pancreat itis under 
precauti ons.  Epi demi ologic studi es have indicated that there is an increased incidence and 
prevalence o f pancreatit is in per sons wit h T2DM.
To enhance understanding of the natural variability o f pancreat ic enzymes in the T2DM 
popul ation and to assess for any  potential  effects of LY3298176 on the exocrine pancreas, 
amylase and lipase values will be monitored in all current and f uture clinical  trials wi th 
LY3298176.
Addit ional monitoring will be requested for amylase or lipase values ≥3X ULN at any  visit after 
rando mizat ion, even in asymptomat ic patients/subjects (see figure below).  Lipase and amylase 
may also be obtained at any  time during the clinical trials for any patient/subject suspected of 
having symptoms suggestive of pancreatit is (such as severe GIsigns and/or symptoms), at the 
investigator’s discret ion.
Acute pancreat itis is an AE defined as an acute inflammatory  process of the pancreas that may 
also invo lve peripancreatic tissues and/or remote organ systems.  The diagnosis of acute 
pancreat itis requires 2 of the fo llowing 3 features:
abdo minal pain charac teristic of acute pancreatit is
serum  amylase and/or lipase > 3X ULN
characterist ic findings of acute pancreat itis on computed tomography  scan or 
magnet ic resonance imaging
Most patients/ subjects wi th acute pancreat itis experience abdo minal pain that is located generally 
in the epigastrium and radiates to the back in approximately  half the cases.  The pain is often 
associ ated wi th nausea and vo miting.  However, experience wit h GLP -1 agoni sts has 
demonstrated that som e patients/
subjects asymptomat ic for classic pancreat itis may demo nstrate 
significant el evations of lip ase and/or amylase.  For patients/ subjects considered by invest igators 
to be asymptomatic for pancreatit is, but whose value(s) for lipase and/or amylase are ≥3X ULN, 
an algorithm is in place to fo llow these patients/subjects safely and to quickly reach/or not a 
diagnosis of pancreat itis.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 67
LY3298176Abbreviations:  GLP =glucago n-like peptide; HV =healthy  volunteers; LY =LY3298176; 
PB=placebo; T2DM =type 2 diabetes mellitus; Wkly =weekly.Pancreatic Enzymes:  Safety  Monitoring Algorithm
In Patients without Symptoms of Pancreatitis1,2
Follow this algorithm when the value(s) for serum amylase and/or lipase are =3x upper limit of normal (U LN)
Test A/L every 4 Weeks 
(More Frequently if Protocol Visit  
Schedule is < 4 weeks)
Negative Imaging ResultsStop Injectable Study Drug5
Consult for Assessment and Management 
Assess for Causes of Pancreatitis 
Notify LillyRetest within 24 -72 hours
Send sample to LaboratoryAmylase and/or Lipase (A/L3) =3X ULN
A/L Not Decreasing
4.  Abdominal imaging is most valuable when performed 
at the time of elevated enzyme values.  If in the opinion 
of the radiologist or investigator, it is safe for the 
patient/subject to receive contrast, an enhanced 
abdominal CT is preferred. MRI is also an acceptable 
imaging modality.3. A/L = amylase and/or lipase. Either or both 
enzymes can be used to meet the algorithm criteria.   
5. At a minimum, order a CBC and a pancreatic 
panel (which includes LFTs, calcium and 
triglycerides). Record all concomitant 
medications.A/L Decreasing
Repeat Abdominal Imaging4
as Soon as Possible After 
Confirmation of Laboratory Values  
1. Symptomatic –related primarily to abdominal pain 
consistent with pancreatitis; however, in the opinion of 
the investigator severe nausea and vomiting plus
other symptoms consistent with pancreatitis may be
considered symptomatic as well.  
2. If in the opinion of the investigator, the patient 
has symptoms of acute pancreatitis:
(a) Stop injectable study drug 
(b) Consult for assessment and management 
(c) Assess for causes of pancreatitis 
(d) Notify LillyIf A/L =3X ULN, perform 
Abdominal Imaging4
Stop Injectable Study Drug5
Consult for Assessment and Management 
Assess for Causes of Pancreatitis
Notify LillyTest A/L Every 4 Weeks Until 
A/L =3X ULN, 
Then Follow Protocol Schedule
Positive Imaging ResultsNegative Imaging Results Positive Imaging Results
Test A/L Every 4 Weeks Until 
A/L =3X ULN, 
Then Follow Protocol Schedule5
5
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 68
LY3298176Patients/s ubjects di agnosed wi th pancreati tis will be discont inued fro m the study .  Invest igators 
will be responsible for following, through an appropriate health care option, these pancreat itis 
AEs until the events resolve or are explained.  AEs that meet the di agnostic cri teria of acute 
pancreat itis will be captured as SAEs.   For all other pancreatic AEs (such as idiopathic or 
asymptomat ic pancreat ic enzyme abnormalit ies), the invest igator will be responsib lefor 
determining the seri ousness of the event (AE or SAE) and the relatedness of the event to study  
drug.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 69
LY3298176Appendix 6. Blood Samplin g Summary
Thesetable ssummarize the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es, and bioanaly tical assays) during the study .  Fewer 
venipunctures and blood draws may actually  occur, but this will not require a protocol 
amendment.
Protocol I8F-MC-GPGA Sampling Summary –Part A
Purpose         Blood Volume 
per Sample (mL)Maximum Number 
of Blood SamplesMaximum Total 
Volume (mL)
Screening tests a 17 1 17
Clinical laboratory tests a 11 6 66
LY3298176 p harmacokinetics 6 11 66
Potential additional LY3298176 
pharmacokinetic samples6 3 18
Blood discard for cannula patency 0.3 5 1.5
Glucose only samples 2 5 10
Point of care safety glucose 0.3 15 4.5
Pharmacodynamics
   Lipids 2.5 2 5
   Fasting insulin 2 2 4
Immunogenicity 6 4 24
Pharmacogenetics 10 1 10
Storage sample 10 2 20
Total 246
Total for clinical purposes 250
aAdditional samples may be drawn if needed for safety purposes.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 70
LY3298176Protocol I8F -MC-GPGA Sampling Summary –Part B
Purpose           Blood Volume 
per Sample (mL)Maximum Number 
of Blood SamplesMaximum Total 
Volume (mL)
Screening tests a 17 1 17
Clinical laboratory tests a 11 10 110
LY3298176 pharmacokinetics 6 13 78
Potential additional LY3298176 
pharmacokinetic samples6 3 18
Blood discard for cannula patency 0.3 28 8.4
Glucose only samples 2 4 8
Pharmacodynamics 0
   Adiponectin 4 3 12
   Lipids 2.5 3 7.5
   Cortisol 2.5 1 2.5
   Oral glucose tolerance test 4 15 60
   Acetaminophen 2 33 66
Immunogenicity 6 7 42
Pharmacogenetics 10 1 10
Storage sample 10 5 50
Total 489.4
Total for clinical purposes 490
aAdditional samples may be drawn if needed for safety purposes.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 71
LY3298176Protocol I8F -MC-GPGA Sampling Summary –Part C
Purpose         Blood Volume 
per Sample (mL)Maximum Number 
of Blood SamplesMaximum Total 
Volume (mL)
Screening tests a 25 1 25
Clinical laboratory tests a 7 10 70
LY3298176 pharmacokinetics 6 13 78
Potential additional LY3298176 
pharmacokinetic samples6 3 18
Blood discard for cannula patency 0.3 28 8.4
Glucose only samples 2 4 8
Pharmacodynamics 0
   Adiponectin 4 3 12
   Lipids 2.5 3 7.5
   Cortisol 2.5 1 2.5
   Oral glucose tolerance test 4 15 60
   Acetaminophen 2 33 66
Hemoglobin A1c 2 4 8
Bone Biomarkers 8 2 16
Immunogenicity 6 7 42
Pharmacogenetics 10 1 10
Storage sample 10 5 50
Total 481.4
Total for clinical purposes 490
aAdditional samples may be drawn if needed for safety purposes .  Part C laborato ry samples will be analyzed at 
thecentral lab oratory.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 72
LY3298176Appendix 7. Reasonably  Anticipated Serious A dverse 
Events
Reasonably Anticipated Serious Adverse Events
Indication or Study Population:  Type 2 Diabetes Mellitus
Group 1:  Anticipated comorbidities expected to be reported as serious adverse events in clinical studies:
Myocardial infarctio n (fatal and no nfatal) a
Cerebral vascular a ccident (fatal and nonfatal) b
Myocardial i schemia c
Peripheral v ascular disease d
Infections
Group 2:  Events which may or may not be anticipated comorbidities of type 2 diabetes mellitus, may infrequently 
be reported as serious adverse events in clinical studies:
Retinopathy e
Nephropathy f
Neuropathy g
Sudden death and cardiovascular death not due to myocardial infarction or stroke
Cardiac failure
Diabetic ketoacidosis
Diabetic foot
Fractures
Neoplasia
Hypoglycemia
Hyperglycemic hyperosmolar syndrome or state
Examples of terms in the categories above include, but are not limited to:
aAcute myocardial in farction, myocardial infarction .
bCerebrovascular accident, stroke, cerebral infarct, ischemic cerebral infarction, ischemic st roke, transient 
ischemic attack .
cAngina, unstable angina, acute coronary syndrome, coronary artery disease, coronary artery bypass graft, 
percutaneous coronary i ntervention, coronary angioplasty .
dPeripheral vascular disease, diabetic peripheral vascular disease, diabetic vascular disease, carotid 
endarterectom y, peripheral revascularization .
eBlindness, proliferative retinopathy, nonproliferative (background) r etinopathy, diabetic retinopathy, retinal laser 
coagulatio n, photocoagulation, loss of vision .
fDiabetic nephropathy, renal failure, acute renal failure, renal insufficiency.   Should not include terms associated 
with prere nal azotemia due to dehydration .
gPeripheral neuropathy, mononeuropathy, autonomic neuropathy, orthostatic or postural hypotension .
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 73
LY3298176Appendix 8. Protocol A mendment I 8F-MC-GPGA (f) 
Summary
A Single -and Multiple -Ascending Dose Study in Healthy  
Subjects to Investigate the Safety , Tolerability , 
Pharmacokinetics, and Pharmacody namics of 
LY3298176 and Multiple Doses in Patients with Ty pe 2 
Diabetes Mellitus
Overview
Protocol  I8F-MC-GPGA , A Single -and Mult iple-Ascending Dose Study in Healthy Subjects to 
Investigate the Safet y, Tolerabilit y, Pharmacokinetics, and Pharmacodynamics of LY3298176 
and Mult iple Doses in Patients with Ty pe 2 Diabetes Mellitus ,has been amended.  The new 
protocol  is indicated by  Amendment ( f) and will  be used to conduct the study  in place of any 
preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are as fo llows:
Addit ion of text summarizing preliminary safety  and tol erabili ty data f rom the com pleted 
Parts A and B of this study .
Addition of language to expand the upper end of the dosing range from 10 mg to 15 mg. 
Clarified that pati ents/subjects may  remain at the CRU as needed for safet y follow -up 
based on clinical judgment of the principal invest igator. 
Updated numbers of partici pants enrolled and needed to complete to allow for the 
addition of  up to two addi tional cohorts. 
Updated the margins o f safety  table based on human exposure data from Parts A and B of 
this study . 
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 74
LY3298176Revised Protocol Sections
Note: All deletions have been i dentified by strikethroughs .
All additions have been ident ified by the use of underscore.
3.2 Background
Preliminary safet y and tol erabili ty data:
In Part A (single -ascending dose [SAD] portion) of this study , more than 50 healt hy subjects 
received study  drug wi th doses of LY3298176 ranging fro m 0.25 m g to 8 m g.  Single doses of 
study  drug were generally  well tolerated .  Gastrointestinal (GI) events (loss of appet ite, bloating, 
nausea, vo miting,etc.) were the most commonly reported adverse events (AEs).  At the 8 -mg 
dose l evel, the m ajority of subjects experienced drug -related GI events   Two of the subjects who 
received 8 mg reported AEs of nausea and vo miting th at requi red treatm ent wi th antiemetics and 
intravenous fluids.   Further dose escalat ion was therefore stopped.
In Part B ( multip le-ascending dose [ MAD] portion) of this study, more than 30 healt hy subjects 
have b een dosed in cohorts of 4 weekly  SC fixed doses of 0.5 m g, 1.5 m g, and 4.5 m g; and an 
additional titration regimen cohort of 5 mg for 2 doses (Weeks 1 and 2), 8 mg (Week 3), and 
10mg (Week 4).  Similar to Part A, the most commo nly reported AEs have been G I events, 
including loss of appet ite, nausea, bloat ing, heartburn, and vo miting.  A m ajority of the AEs have 
been reported following the first week of dosing, with fewer AEs being reported after the third 
and fourth doses.   The 8 -mg dose was better tolerated in this titration approach as compared with 
the single 8 -mg dose evaluated in Part A   The limit s of tol erabili ty were not reached in the 
multiple-dose escalation in healthy subjects.
Part C of this study  is current ly ongo ing.  A group of T2DM patients has received a fixed dose of 
5 mg for 4 weeks. GI events were the most commonly  reported adverse events in these patients. 
LY3298176 appears to be better tolerated by T2DM patients who received 5 mg doses compared 
to healt hy subjects who received 4.5 mg in Part B of the study .A second group of T2DM 
patients i s current ly being evaluated in Part C using a titration approach with a dosing scheme o f 
5 mg (Week 1), 5 m g (Week 2), 10 mg (Week 3), and 10 mg (Week 4). GI events (decreased or 
loss of appet ite, feeling bloated, nausea, vo miting, etc ) have been reported following the first 
two doses of 5 mg. Preliminary  data regarding the 10 mg dose indicat es that LY3298176 appears 
to be tol erated in this titration approach.
5.1.Overall Design
The pl anned LY3298176 doses for this study  range fro m 0.25 m g up to 10 15 mg LY3298176 
(Secti on5.5).Initially, i t was planned to explore doses up to 10mg ;however, based on a 
preliminary review of safet y,tolerabilit y, and PK data, the upper end of the dose range was 
increased from 10 mgto 15 m g.  Dulaglut ide will be provided as a 1.5 -mg SC dose.
I8F-MC-GPGA( f)Clinical Pharmacology Protocol Page 75
LY3298176The invest igator or qualified designee will review all avail able inpat ient safet y data before 
discharging pat ients/subjects fro m the CRU on the morning o f Day 4, provi ded they  are deemed 
medically fit by  the invest igator.  Patients/subjects may be required to remain at the CRU longer 
than Day 4 at the investi gator’ s discret ion.  Safet y, as assessed by  AEs, clinical safet y laboratory  
tests, vi tal signs, 12 -lead ECGs, concomitant medications, and medical assessments ,will be 
reviewed by the sponsor and invest igator before each dose -escalat ion decisio n.
During the stud y, patients/subjects m ay rem ain at the CRU as needed for safet y follow-up based 
on clinical judg ment of the principal invest igator. 
5.1.3. Multiple -Dose Evaluation in Patients with Type 2 Diabetes 
Mellitus (Part C)
Part C m ay be ini tiated based on the eva luation of safet y and tolerabilit y data f rom Part B 
(MAD).
Amendment to Part C 
The protocol has been amended to allow the addit ion of up to 2cohorts (up to 15 patients each) 
of T2DM pati ents to enable assessment of doses up to 15 mg through dose titratio n.
5.2 Number of Participants 
Approximately 143 healt hy subjects and up to approximately 25 55 patients with T2DM m ay be 
enrolled so that approximately 112 healthy subjects and up to approximately 20 40 patients 
complete the study .
5.5 Justification for Dose
Protocol Amendment (f)
Healthy subjects were given single doses up to 8 mg near the limits of tolerabilit y in Part A, and 
4 fixed weekly doses of 0.5 mg, 1.5 mg,and 4.5 mgand up to 10 mg as part of a titration scheme 
in Part B. The limits o f tolerabilit y were not reached in either Part A or B of this study . In 
Part C, LY3298176 was given to patients with T2DM in a fixed 5-mg weekly dose cohort and a 
titration cohort of 5 m g, 5mg, 10 mg,and10 m g over 4 weekly doses. Based on better 
tolerabilit y of LY3298176 in T2DM patients compared wi th healt hy subjects and updated 
margins of safet y based on human exposure data from Parts A and B of this study (see Table 
GPGA.5.2 ), the protocol is amended to eval uate a maximum dose of LY32981 76 up to 15 mg in 
T2DM pati ents as part of up to 2additional t itration schemes in Part C of this study .
I8F-MC-GPGA(f) Clinical Pha rmacology Protocol Page 76 
LY3298176  
Table GPGA.5.2. Updated Margin of Safety for Subcutaneous Administration of 
LY3298176 Based on Preliminary Human PK Data  
 Dose Dose 
    AUC Exposure 
Multiple 
to Human 
Starting 
Dose Exposure 
Multiple to 
Human 
Maximum 
Dose (mg/kg) (mg/m 2) (µg•hr/mL) 
Human 
maximum dose 
(15  mg) b 0.214 b 7.92     342 c  -   
Rat NOAEL d 1.5 8.85 134 h 0.68 e 
Monkey NOAEL
f 0.15 1.8     115 i   0.33 g 
Footnote:  Refer to Table GPGA 5.1. 
 
Appendix 6. Blood Sampling Summary   
I8F-MC-GPGA(f) Clinical Pha rmacology Protocol Page 77 
LY3298176 Protocol I8F-MC-GPGA Sampling Summary – Part A 
 
Purpose Maximum Blood Volume 
per Sample (mL) Maximum Number 
of Blood Samples Maximum Total 
Volume (mL) 
Screening tests a 17 1 17 
Clinical laboratory tests a 11 6 66 
LY3298176 pharmacokinetics 6 11 66 
Potential additional LY3298176 pharmacokinetic samples 6 3 18 
Blood discard for cannula patency 0.3 5 1.5 
Glucose only samples 2 5 10 
Point of care safety glucose 0.3 15 4.5 
Pharmacodynamics    
   Lipids 2.5 2 5 
   Fasting insulin 2 2 4 
Immunogenicity 6 4 24 
Pharmacogenetics 10 1 10 
Storage sample 10 2 20 
Total   246 
Total for clinical purposes  250 
 Protocol I8F-MC-GPGA Sampling Summary – Part B 
 
Purpose Maximum Blood Volume 
per Sample (mL) Maximum Number 
of Blood Samples Maximum Total 
Volume (mL) 
Screening tests a 17 1 17 
Clinical laboratory tests a 11 10 110 
LY3298176 pharmacokinetics 6 13 78 
Potential additional LY3298176 pharmacokinetic samples 6 3 18 
Blood discard for cannula patency 0.3 28 8.4 
Glucose only samples 2 4 8 
Pharmacodynamics   0 
   Adiponectin 4 3 12 
   Lipids 2.5 3 7.5 
   Cortisol 2.5 1 2.5 
   Oral glucose tolerance test 4 15 60 
   Acetaminophen 2 33 66 
Immunogenicity 6 7 42 
Pharmacogenetics 10 1 10 
Storage sample 10 5 50 
Total   489.4 
Total for clinical purposes  490 
a Additional samples may be drawn if needed for safety purposes. 
I8F-MC-GPGA(f) Clinical Pha rmacology Protocol Page 78 
LY3298176 Protocol I8F-MC-GPGA Sampling Summary – Part C 
 
Purpose Maximum Blood Volume 
per Sample (mL) Maximum Number 
of Blood Samples Maximum Total 
Volume (mL) 
Screening tests a 25 1 25 
Clinical laboratory tests a 7 10 70 
LY3298176 pharmacokinetics 6 13 78 
Potential additional LY3298176 pharmacokinetic samples 6 3 18 
Blood discard for cannula patency 0.3 28 8.4 
Glucose only samples 2 4 8 
Pharmacodynamics   0 
   Adiponectin 4 3 12 
   Lipids 2.5 3 7.5 
   Cortisol 2.5 1 2.5 
   Oral glucose tolerance test 4 15 60 
   Acetaminophen 2  33 66 
Hemoglobin A1c 2 4 8 
Bone Biomarkers 8 2 16 
Immunogenicity 6 7 42 
Pharmacogenetics 10 1 10 
Storage sample 10 5 50 
Total   481.4 
Total for clinical purposes  490 
 
Leo Document ID = 9607714e-be41-4d6c-9056-616ee437eccb
Approver: 
Approval Date & Time: 06-Feb-2017 01:31:13 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 06-Feb-2017 17:58:11 GMT
Signature meaning: Approved
PPD
PPD